Next Article in Journal
Effect of Cardiac Rehabilitation on Left Ventricular Diastolic Function in Patients with Acute Myocardial Infarction
Previous Article in Journal
Assessment of the Association of COPD and Asthma with In-Hospital Mortality in Patients with COVID-19. A Systematic Review, Meta-Analysis, and Meta-Regression Analysis
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Clinical and Forensic Aspects of the Different Subtypes of Argyria

by
Luís Mota
1,* and
Ricardo Jorge Dinis-Oliveira
1,2,3,*
1
Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal
2
IINFACTS-Institute of Research and Advanced Training in Health Sciences and Technologies, Department of Sciences, University Institute of Health Sciences (IUCS), Advanced Polytechnic and University Cooperative (CESPU), CRL, 4585-116 Gandra, Portugal
3
UCIBIO-REQUIMTE-Applied Molecular Biosciences Unit, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
*
Authors to whom correspondence should be addressed.
J. Clin. Med. 2021, 10(10), 2086; https://doi.org/10.3390/jcm10102086
Submission received: 29 March 2021 / Revised: 29 April 2021 / Accepted: 11 May 2021 / Published: 13 May 2021
(This article belongs to the Section Dermatology)

Abstract

:
Argyria encompasses the different cosmetic alterations that can develop if enough silver particles deposit in a specific tissue, typically in the skin, ranging from localized dark-blue macules to a generalized slate-gray/bluish tinge following systemic absorption. This work aims to fully review the state of the art regarding pathophysiology, diagnosis, treatment, and relevant clinical and forensic features of argyria. Argyria has been diagnosed in a wide range of ages, both sexes and varied ethnicities, with no known individual predisposing factors. Ultraviolet radiation with subsequence increases of melanin production aggravates the discoloration due to a reduction in the silver deposits. Physical examination and silver exposure in the anamnesis can be highly suggestive of the diagnosis, but a histopathological analysis with Energy-Dispersive X-ray Spectroscopy is required to unequivocally determine the discoloration etiology. Safe and effective treatment has only been accomplished with laser techniques, though only a few cases have been reported and with limited follow-up time. In conclusion, argyria typically has an occupational or iatrogenic etiology. It should be suspected when a patient presents with typical skin or eye lesions. A seemingly viable treatment modality, with laser technology, is finally within the horizon.

1. Introduction

Argyria refers to inert silver deposition in a tissue, typically the skin, resulting in characteristic blue/gray spots or a diffuse hue, but also possibly darker or brownish [1,2,3,4,5,6]. It occurs following excessive accidental voluntary cumulative silver exposure by the most varied causes. It is mainly a cosmetic condition whose clinical presentation will vary according to the subtype as describe below [2,3,7,8,9].
The state of the art concerning pathophysiology, clinical presentation, diagnosis, therapeutic modalities, and forensic features of argyria is reviewed, and the main gaps in current knowledge, where future research ought to be focused, are highlighted.

2. Materials and Methods

An exhaustive search was carried out in PubMed database without a limiting period concerning pathophysiology, signs and symptoms, history and physical examination, diagnostic, treatment, and forensic aspects of argyria. The keyword “argyria” was searched in articles written in all languages. Additionally, the keyword was crossed with diagnosis, toxicokinetics, amalgam tattoo, ocular argyrosis, azure lunula, and treatment. Furthermore, retrieved journal articles, as well as books and governmental documents, were also reviewed for possible additional publications related to this topic. A total of 290 scientific documents, including books, articles, and government documents, were considered for this review.

3. Chemistry and History of Silver

Silver derives from the Anglo-Saxon “seofor” and “siolfur”, and it is a chemical element, solid at room temperature, classified as a transition metal (atomic number 47), of period 5 and group 11 of the Periodic Table. Its symbol is Ag, which derives from its Latin name argentum [10,11]. It is a rare, naturally occurring element found as a soft, “silver”-colored metal in its pure form, but in the environment, it is mostly found in its typical oxidation state (+1) combined with other ions or molecules, such as sulfide, chloride, and nitrate, which give the compound a color ranging from dark-gray/black to powdery white [11,12]. Of all known metals, silver has the highest electrical and thermal conductivity and possesses the lowest contact resistance [11].
Silver value has been recognized since ancient times, as it was likely separated from lead as early as 4000 BC [10]. Silver metal is used for jewelry, silverware, electronic equipment, and dental filling. Soluble inorganic silver salts (e.g., silver nitrate and silver sulfide) are strongly bactericidal, and particularly silver nitrate (1%) had been used immediately after born to prevent gonococcal ophthalmitis in newborns. Antibiotic ointments have replaced silver nitrate for this indication. Silver sulfadiazine slowly releases silver and is used to suppress bacterial growth in patients with second- and third-degree burns wounds. Nevertheless, silver medicinal value is often overemphasized, and unsubstantiated claims for treating diverse diseases are widely reported. Occupational exposure occurs mainly from inhalation of silver fumes and dust in different settings; for instance, silver halide is used in the manufacture of photographic plates [13,14].
There is no essentiality for silver, and dietary intake is in the range of 0.4 to 27 μg/day, which is much less than the silver intake from medicinal uses [15]. For drinking water disinfection, World Health Organization permissible level is reported to be 0.1 mg Ag/L [16]. One of the recent applications of silver is in nanoparticles (AgNP), materials with sizes ranging from 1 to 100 nm, containing 20 to 15,000 atoms of silver. Because of their antimicrobial activity, AgNP are used in a variety of consumer products, including medical devices, disinfectants, appliances, textiles, and water treatment [15,17].

4. Toxicokinetics of Silver

Silver is primarily absorbed by the gastrointestinal tract, lung, and skin [15,16,18]. Up to 10% of ingested silver, a value expected to vary with individual characteristics (at least age, health, and nutritional status) and the degree of ionization/solubility of the silver compound, is absorbed in the gastrointestinal tract [3,13,19,20,21,22]. Metallic silver and insoluble silver compounds are not readily absorbed and pose a minimal health risk, unlike particulate or colloidal silver, whose toxicity comes from released ionic particles [13,15]. Inhalation of aerosolized particles, typically occurring in the occupational setting, is also a relevant pathway for silver absorption, but the toxicokinetic properties of this process remain even more uncharacterized [21,23,24,25,26]. There has been some consensus around 0.01 mg/m3 as the threshold limit value for daily silver occupational exposure, but a lower limit of 0.1 mg/m3 for metallic silver is becoming more common, as it shows less propensity to cause argyria than its ionic, more soluble and absorbable counterpart [27].
Silver is transported in the bloodstream as a colloid, in its ionic form (Ag+), stabilized by complexing with proteins, mainly albumin but also globulins [20,24,28,29]. It is widely distributed to most tissues, such as muscle, cerebellum, spleen, duodenum, heart, lung, liver, and kidney [15]. It is not clear whether silver crosses the blood-brain barrier, although several studies indicate accumulation in specific areas of the brain [15]. Indeed, silver deposition has been documented in the blood-brain barrier (vascular endothelium and astrocytes), the blood-cerebrospinal fluid barrier (choroid plexus), and the cerebrospinal fluid itself [30,31,32]. Moreover, Landas et al. [33] reported a postmortem evaluation with silver deposition in circumventricular organs and hypothalamic nuclei, suggesting silver’s eventual passage to the central nervous system. Nevertheless, the state of the art is far from being clarified.
The primary routes of exposure for AgNP include excretion occurring predominantly in the bile but also through the urinary system in a much lesser amount [3,19,20,28,34,35,36]. Indeed, biliary excretion is important in the homeostasis of several metals, notably copper, manganese, cadmium, selenium, gold, silver, and arsenic [37].

5. Argyria Subtypes

Silver deposition has been documented in several anatomic places such as the skin, eyes, kidneys, and liver, but it might happen in virtually every organ, which is coherent with silver’s general affinity for stromal tissue and basement membranes and, as in the skin, this deposition has not been definitely associated with any harmful effects [20,38,39,40,41,42,43]. In the following sections, different types of argyria are reviewed.

5.1. Generalized Argyria

Generalized argyria (GA; Figure 1) emerges following silver systemic exposure and its uptake by the dermis [3,5,8,24,44,45]. This leads to a gray/blue saltish or metallic diffuse skin pigmentation, which becomes evident predominantly in sun-exposed areas [3,5,38,44,46,47,48]. Patients were most commonly present with gradually aggravating face and neck discoloration with a history of oral but also occupational aerosolized exposure to silver-containing products [3,13,28,44,49,50,51,52,53,54]. Different minimal amounts of elemental silver cumulative oral intake able to produce GA have been suggested, ranging from 2 to 30 g, but such values provide incomplete information unpaired with a time window [8,19,29,39,55,56,57].
Azure lunula is a bluish discoloration of the fingernails, more precisely of the lunula (Figure 2), but with the possible extent to the proximal half of the fingernail that was frequently accompanying GA [6,36,47,50,61,62]. Another possible early sign of GA is acquired pigmentation of the oral mucosa; unlike amalgam tattoos, a diffuse gray/blue tinge will be seen [1,6,7,49,58,63,64,65,66].

5.2. Localized Argyria

Localized argyria (LA; Figure 3) is less commonly seen, being caused by local silver deposition following skin incisions or percutaneous absorption via sweat gland pores [3,8,28,70,71,72,73,74,75,76,77,78,79,80]. This results in macular lesions or spots-clusters, confined to where the silver impregnation occurred and with coherent morphology, whose color, compared to GA’s, tends to be darker, sometimes almost black [8,73,81,82,83]. Patients most commonly present with complaints of asymptomatic lesions in a site of previous trauma, cautery with silver devices, or prolonged contact with silver-containing objects, creams, or solutions, as it occurs in the hands and forearms of silver-handling workers [2,75,81,82,84,85,86,87].
Amalgam tattoo (Figure 4) is probably the most common form of LA [91,92,93]. It is is a common and easily recognizable entity that results from the impregnation of silver-contained dental amalgam into oral mucosa following tooth restoration procedures [92,94,95,96,97,98]. A flat, dark-blue mucosal lesion near a restored tooth is highly indicative of an amalgam tattoo, with size varying from small, millimetric lesions to larger ones, with a minority of these even exhibiting radiopacity and potentially triggering a foreign body reaction [92,95]. Besides silver, it is important to highlight that dental amalgams could also present silver, tin, copper, and zinc, which may also have a role in the development of amalgam tattoos [99]. A biopsy might be useful, especially to rule out melanoma [92,95,96,100]. Other less common forms of LA reported are in the nasal [101,102], tracheal and bronchial mucosa [103], urinary tract [104,105,106,107], vagina [108], and penis [109].

5.3. Argyrosis

Argyrosis is a particular argyric manifestation evidenced by the ocular silver deposition (Figure 5) that can occur in GA [6,34,47,49,54,111,112], but also as a LA form [113,114,115,116]. It is mostly detected in the cornea, bulbar and palpebral conjunctivae, and lacrimal caruncle [113,114,117,118,119,120]. Its appearance ranges from small, darker lesions to a more disperse tinge, somewhat parallelly to LA and GA, and with greater heterogeneity concerning coloration, as greenish and brownish tones might be displayed other than the typical gray/blue [121,122].

6. Pathophysiology of Argyria

Covalent adduct formation is common with electrophilic compounds because they react with nucleophilic atoms in proteins and nucleic acids. In general, soft electrophiles prefer to react with soft nucleophiles (low charge-to-radius ratio in both), whereas strong electrophiles react more readily with strong nucleophiles (high charge-to-radius ratio in both), such as the oxygen in nucleic acids. Metal ions as silver and mercury are soft electrophiles that react covalently with soft nucleophiles, particularly thiol groups, such as cysteine-abundant collagen fibers and proteoglycans in the extracellular matrix [3,29], and metallothioneins intracellularly, whose synthesis is induced after cellular silver intake [24,30,77,124].
Discoloration develops following ultraviolet exposure since silver ions undergo photoreduction to atomic silver, which can be oxidized mainly to low-solubility and chemically stable compounds such as silver sulfide (Ag2S) and silver selenide (Ag2Se) [13,29,125,126,127,128]. This photoreduction process is equivalent to the darkening of photographic film following light exposure and leads to argyria and explains its greater notoriety in sun-exposed areas [9,19,79,129,130]. In the absence of light as occurs in the gastrointestinal tract, argyric discoloration may be due to the role of tissue enzymes or other redox systems in the conversion of silver to its elemental form [40,112,130,131]. The subsequent formation of very low-solubility complexes can be compared to photographic toning/metal tarnishing, as it increases the stability of the silver aggregates and influences the color of the acquired pigmentation, and it also restraints even further silver’s interaction potential with biological structures, providing some explanation to its lack of toxicological effects and foreign body reaction generation [9,98,127,128].
There is evidence of silver found intracellularly, lying in the cytoplasm or bound to lysosome-like structures inside histiocytes and fibroblasts, suggesting a cellular uptake role in its cleanup, but not in any way near an extent that enables pigmentation resolution; therefore, silver is clearly found mainly in extracellular locations [3,29,80,81,128,132,133,134,135,136].
After silver gains access to the dermis or other tissues, either carried by the bloodstream (leading to GA) or localized (leading to LA), it deposits in a predictable pattern, as shown by histopathological and ultrastructural studies [51,70,76,81,85,137]. Typically, the silver particles settle in the connective tissue underlying epithelial surfaces, arranged in rows of granules, with a propensity for the basement membranes of blood vessels, eccrine sweat glands, and other dermal adnexa, but also depositing along dermal elastic fibers and the dermo-epidermal junction, while staying clear of the epidermis [4,7,55,64,73,79,81,85,133,134,138,139,140,141]. Of note, the outermost skin layer also influences the macroscopical appearance of the discoloration; since it reflects light in the violet/blue spectrum more than in longer wavelengths, argyria colors are usually perceived as blue/gray at clinical evaluation. In anatomic places where stratum corneum is thicker, color may be less intense; indeed, argyric patients’ hands, palms appear less pigmented than the dorsa, despite having a similar concentration of silver particles in the dermal tissue [45,71,77,79,142,143,144,145].
Also playing a role in skin darkening is silver’s stimulatory effect on melanin production, which appears to be one of the few direct effects of silver particles in surrounding tissues, possibly via an increment on tyrosinase enzyme activity [9,77,78,84,125,146,147].
Regarding azure lunula, the pathophysiology explaining the prevalence of discoloration in the lunula in comparison to nail beds is not yet clarified. What is known is that the nail plate is translucent, allowing the visualization of the underlying nail bed. It also grows thicker distally, being thinner in the lunula. With nail formation, cells move forward from the lunula (keratogenous zone), suffering fragmentation until they are predominantly anucleated, eosinophilic, and arranged in very compact sheets [148]. These two factors (nail plate thickness variation and changes in keratinocytes along the nail plate) might play a role in the color disposition found in argyric nails (azure lunula), as well as a richer vascularization toward the nail matrix when compared to the nail midbed [148].
In the eye, silver deposits exhibit a clear predilection for corneal Descemet’s membrane, but it can also be found in Bowman’s membrane, the stromal tissue in-between, both bulbar and palpebral conjunctiva and the lacrimal caruncle [25,58,102,113,149,150,151,152]. When the lacrimal sac is visualized (following dacryocystectomy), it often displays the pigmentation as well and in a striking fashion, with a strong black tone [114,153,154]. Reports of crystalline lens silver deposits have also been made [54,114,149,155]. In the posterior segment of the eye, silver accumulation is speculated about, following reports of retinal pigment epithelium changes, drusenoid deposits, and dark choroids in fluorescein angiogram, but a necessary causal relationship was not yet clearly established [111,156,157,158]. Following local contact, silver episcleral and periocular inoculation, such as in the eyelids, can also be present [23,86,159,160,161]. Silver’s histopathological pattern of deposition will also be similar whether there’s local implantation or systemic absorption, behaving as seen elsewhere in the body: settling in epithelial basement membranes and subepithelial connective tissue, predominantly extracellularly, and undergoing redox reactions that aggravate the pigmentation and stabilize the silver compounds [102,112]. Following systemic exposure, ocular argyrosis, more specifically corneal and/or conjunctival involvement, is seemingly the earliest indicator of silver accumulation in the body, with its deposition in these tissues being often documented before any other clinical signs of argyria [120,162]. Some authors have even claimed that there is a correlation between the number of eye deposits/degree of coloration and the length of silver exposure [122,163].

7. Diagnosis of Argyria

Argyria is often overlooked as a differential diagnosis of pigmented lesions, given its rarity [8,45,83,164]. Any of these findings might correspond to argyria: a slate-gray/bluish change of the complexion in sun-exposed areas, localized dark-blue lesions, eye gray/brown/dark spots or conjunctival pigmentation, or the characteristic nail changes seen in azure lunula [34,46,48,61,73,82,115,165]. Silver product exposition, as in oral silver consumption in a GA-suitable patient, a previous dental restoration in a patient presenting with amalgam tattoos, or acupuncture history in a patient with dispersing cutaneous LA lesions, can be highly indicative of argyria [5,53,86,89]. Different causes have been documented, and Table 1 compiles all major causes of argyria.
The timespan for the onset of the pigmentation might vary from days to several years, and it then becomes ever lasting, making the diagnosis of argyria not discardable regardless of the amount of time passed since exposition and first-time pigmentation observation [8,81,83,87,134,164,165,188,222,244]. These should prompt a thorough anamnesis to ascertain if there is any kind of pathological or toxicological justification for these alterations and to establish a differential diagnosis (Table 2).

7.1. Signs and Symptoms Related to Argyria

Signs and symptoms derived from silver exposure other than the cosmetic changes are usually absent, even after systemic absorption, suggesting that silver has low toxicity in humans [3,6,9,13,58,131,132,147,261]. The silver deposits in the skin do not seem to cause any harm to the surrounding tissues, being the psychosocial embarrassment derived from the aesthetic impact usually the most negative consequence, sometimes even leading to social withdrawal [9,43,47,55,132,223].
Patients with OA have reported visual symptoms, most commonly nyctalopia [54], and presented with concomitant comorbidities, such as glaucoma [151,163], cataract [114,149,218,262], diabetic retinopathy [111], as well as posterior eye segment changes somewhat coherent with the functional complaints [157,158], but without direct link to the silver deposition itself [156,162,263]. This inconsistency, alongside several OA patients lacking any visual complaints, has contributed to some consensus regarding the seemingly innocuous silver deposition in the eye, though this claim still needs a more robust foundation [21,113,261,263,264].
As silver has been found to settle in several tissues, concern has been raised regarding possible systemic toxic effects. Regarding the kidney, a decrease in the glomerular filtration rate has been suggested, after reports of nephrotic syndrome [265], membranous nephropathy [266], and acute or chronic renal failure [22,181,267] following argyria, but a causal relationship could not be indisputably defined. Still, it should be highlighted that the development of an antineutrophil cytoplasmic antibodies (ANCA) negative pauci-immune glomerulonephritis in a 47-year-old woman with a T-cell lymphoma has been reported, suggesting that the silver deposition in glomerular basement membranes, though seemingly innocuous, might be the trigger for leucocyte-mediated aggression in patients with a background of auto-immunity disorders [268].
Liver toxicity following silver deposition has also been suggested but, apart from transient hepatic enzyme elevation with no clinical significance, no evidence of pathological liver processes caused by silver accumulation has been found [5,55,182,223,269]. Indeed, most argyric patients, as well as individuals exposed to silver without clinical signs of argyria, present with corresponding laboratory parameters within reference values for healthy people [6,48,49,51,52,66,69,132,144,211,212,218,230,263]. Argyric patients might require special attention when radiotherapy is required after a report of a radiation dermatitis possibly explained/aggravated by the dermal silver deposition [215].
Lung fibrosis in silver finishers has also been reported [270,271]. Even though silver’s contribution to said outcome remains speculative, the inhalation of silver dust cannot be ruled out as a causative factor for pneumoconiosis.
It has also been considered that silver exposition might precipitate neurological and/or psychiatric events. There have been reports of argyric patients presenting with diverse neurological clinical pictures, ranging from acute seizures to neurodegenerative disorders or even peripheral neuropathy [32,128,183,195,217,222,272], but the potential causal relationship remains inconclusive as the cases reported are rare and do not allow extrapolation. Regarding argyria affecting psychiatric patients, the possible causal relationship seems to be the opposite, as delusional beliefs often are what leads to unmeasured silver consumption [195,211,214,224,273].

7.2. Medical Exams

To better characterize the suspected pigmentation and exclude the differential diagnosis, histopathological analysis of the affected tissue is particularly important [7]. After conventional tissue section processing and staining with hematoxylin and eosin, the dark deposits may be seen both in bright and dark field microscopy, with the latter being more sensitive as they appear refractile, arranged as described above in the pathophysiology section [7,55,84,87,133,139,213]. Ultrastructural analysis of skin biopsies, but also of the kidney and choroid plexus, allows visualization of electron-dense particles, typically round or ovoid in shape but sometimes more irregular, and with a greater axis ranging from 10 to 1000 nanometers [31,80,127,132,133,140]. Reflectance confocal microscopy has also been used, namely for LA work-up, as it can help quickly excluding melanocytic proliferation [133].
To establish an unequivocal diagnosis, an Energy-Dispersive X-ray Spectroscopy (EDXS) must be undertaken as this technique, whose apparatus is generally attached to electron microscopes, allows identification of the chemical elements found in the granules via analysis of their emitted energy spectrum, making it the gold-standard tool for argyria definite diagnosis [38,39,83,84,132,133,141,164]. While being non-invasive, it presents remarkable specificity and sensitivity (estimated limit of detection of 3 to 4 ppm) for silver, as well as for other chemical elements such as selenium and sulfur, and it might even allow monitoring of subclinical silver deposition in occupationally exposed workers [133,164,274]. Other documented auxiliary diagnostic methods are the neutron activating analysis, which allows determination of the silver content in the skin, hair, urine samples, or the whole body, but the advantages it can bring being routinely used in the clinical setting are scarce [126,275,276]. With resort to atomic absorption spectrometry and, more recently, inductively coupled plasma mass spectrometry [230], measurement of serum and urinary silver levels [9,54], as well as in feces, hair [28,35,263], kidney and liver wet tissue samples [180], might help to determine the body burden of silver, but these parameters have shown to be consistently reliable neither for risk assessment of argyria development nor for diagnosis of the condition [9,28,35,54,180,230,263].
Dermatoscopy is also often employed, particularly in the evaluation of LA, typically exhibiting a dark, dense, and homogenous pigmentation [82,83,87,89,133]. Enei et al. [71] showed that dermatoscopy might allow a peek into some detail of the histopathological pattern: dermal papillary silver seemingly appears as dots, perieccrine pigment as circumferences/ellipses, and the silver along the interpapillary dermis as linear structures. While it cannot diagnose argyria, it may provide helpful information in excluding differential diagnosis [65].
Slit-lamp biomicroscopy is the first step in the diagnostic approach of OA, revealing a particulate pattern in the cornea, but this technique, possibly complemented with confocal microscopy, should be employed for exposure monitoring, or if GA is suspected even without clinical evidence of OA, since cornea’s Descemet’s membrane displays silver deposits quite early following either systemic or local exposition, making slit-lamp examination a sensitive index for both GA and OA [102,117,118,120,157,162,199]. Other ophthalmological tests have also been reported, such as fluorescein angiography, optical coherence tomography, and electroretinogram, but their purpose so far has been mainly to find eye structural and functional changes related to argyria rather than establishing the diagnosis and with extrapolations limited due to the number and type of studies [149,156,157,158,218,222].

8. Treatment

Spontaneous argyria regression or any kind of intermittence cannot be expected, as the silver remains inert in the deposition sites indefinitely; in order words, the pigmentation is permanent without treatment [4,13,19,47,56,131,166]. At this point, the degree of sun exposition will determine the discoloration aggravation, with cessation of silver exposure being critical to avoid worsening of the aesthetical alteration, but seemingly futile in what concerns reverting it [5,34,39,178,223,225]. Therefore, the use of cosmetics can help to mask the discoloration, and sunscreens might be beneficial in preventing further pigmentation when sun exposure is unavoidable [7,36]. At the occupational level, periodic slit-lamp biomicroscopy and monitoring of silver aerial concentration have been suggested to ensure the employees’ safety [120,162,261]. Contrasting with these general findings, Wu et al. [121] reported a case of presumed OA following silver nitrate cautery of the palpebral conjunctiva with clinical and confocal microscopy regression with a follow-up of three years.

8.1. Treatment of Argyria

For a long time, there has not been an effective and safe treatment method for argyria [13,19,26,36,135,141]. Numerous approaches to remove the coloration are reported in the literature, but none with appreciable success: depigmenting creams, chelation therapy with different drugs such as 2,3-dimercapto-1-propanol (i.e., dimercaprol), 2,3-dimercapto-1-propanesulfonic acid (DMPS), sodium thiosulfate, potassium ferrocyanide, potassium iodide, ethylenediaminetetraacetic acid (EDTA), methenamine and D-penicillamine/N-acetyl-DL-penicillamine, hydroquinone and dermal abrasion all proved ineffective in removing silver deposits from the body [26,55,62,127,141,192,200,276,277,278,279]. Some of these chelating agents have been reported to lighten the pigmentation in small skin areas after intradermal injection, particularly sodium thiosulfate and potassium ferrocyanide, but results are inconsistent, and their application to larger areas would be quite incommodious and burdensome, with the risks associated far outweighing the unlikely benefits [19,55,131,178,245].
In the last few years, cases of successful skin pigmentation resolution with conventional tattoo-removal laser techniques have been reported, offering insight in a promising treatment modality that might revolutionize argyria’s natural disease progression and the psychological burden. Both Q-Switched 1064 nanometers Neodymium-doped Yttrium Aluminum Garnet Laser (Q-S 1064 nm Nd:YAG laser) and Q-Switched Picosecond 755 nanometers Alexandrite Laser (Q-S P 755 nm Alexandrite Laser) have been reported to yield satisfactory results. The former, ranging from a fluence of 0.7 to 8 J/cm2, a pulse duration of 5 to 50 ns, a frequency of 5 to 10 Hz, and a spot size of 2 to 8 mm [139,219,223,252,280,281], produced immediate results, restoring the expected skin coloration for each subject in the targeted areas [51,63,142,282]. As with the latter, at least similar efficacy was obtained within reported values of 0.71 to 2.83 J/cm2 regarding fluence, 0.75 ns regarding pulse duration, 3 to 5.5 mm regarding spot size, and 10 Hz regarding frequency [74,216,219,220]. The persistence of restored skin coloration has been reported up to one year after treatment [142,223,252,282]. Otherwise, there has been one report of argyria pigmentation recurrence 11 months after Q-S 1064 nm Nd:YAG laser treatment, despite the patient stating discontinuation of silver exposure, use of facial and body sunscreen with a sun protection factor superior or equal to 30, and resort to physical sun-protective barriers [63,283]. Figure 6 evidence the effect of the treatment with Q-S 1064 nm Nd:YAG laser.
Both procedures provoke very intense pain [280], seemingly greater as fluence increases and more area is to be depigmented [282]. For this reason, technicians have resorted to varied anesthesia techniques, with general anesthesia being offered in some cases [51,142]. Beyond that and a transient inflammation of the skin with edema, erythema, and scaling [74,88], no other significant adverse effects or sequelae have been reported, with adequate healing of the treated areas [51,142,216,219,223,252,281,282].
The precise mechanism behind the disappearance of the pigmentation is not totally clear. It was initially postulated that the silver particles, once laser-targeted, would fragment, with their remnants being phagocytosed and removed from the skin via lymphatic uptake in a similar fashion to what occurs with conventional tattoos; this hypothesis is consistent with the decrease in the number of silver granules observed by light microscopy of post-treatment biopsies [223,252]. However, this mechanism would not be able to explain the macroscopical whitening of the skin obtained right after laser appliance, nor the fact that immediate post-treatment biopsies, taken from normal-appearing skin, revealed persistence of silver particles, which suggests laser treatment affects silver particles’ plasmon resonance, altering its emitted optical spectrum and allowing skin color restoration despite silver persistence [282,283]. It was speculated that Q-S 1064 nm Nd:YAG treatment might reverse the intradermal photoactivated reaction that silver particles go through after sunlight exposure, but their persistence in the skin allows argyria relapse if ultraviolet radiation reaccumulates [283]. Shao et al. [220] recently reported that after Q-S P 755 nm Alexandrite Laser, the silver particles, previously large enough to be seen by light microscopy with hematoxylin and eosin staining, were no longer able to be visualized by this means. Electron microscopy showed that the silver had not been removed from the skin but rather remained in similar locations, only now fragmented; particles went from approximately 25–100 nanometers to 4–15 nanometers, arranged in clusters. Two months after treatment with Q-S 1064 nm Nd:YAG laser, the persistence of perieccrine silver in macroscopically normal-appearing skin areas, documented with scanning electron microscopy, has been reported [282]. These data, along with Mock et al. [284] findings that heat treatment can modify silver nanoparticles’ geometrical shape, altering their emitted light spectrum wavelength, help put together the most robust explanation so far as to why clinical argyria provisional resolution, at least, can be obtained despite silver persistence in the skin and emphasizes the need not discard the possibility of argyria relapse even with silver exposure discontinuation.

8.2. Treatment of Amalgam Tattoo

The treatment of amalgam tattoos has also been an object of attention. The operator should irrigate the intervened area thoroughly to ensure all traces of silver-containing root canal sealer are properly cleaned up and removed to prevent the lesion onset, especially when the procedure requires soft tissue flap reflection [96]. After LA develops, if the lesion is cosmetically unacceptable, surgical excision and transplantation of oral mucosal tissue/free gingival grafting, as well as subepithelial connective tissue grafts, have been reported, with heterogenous results (even with LA resolution, the final aesthetic outcome might not be optimal) [92,206,207,285]. Regarding secondary prevention, periradicular surgery to remove the amalgam restorations and reduce the amount of dispersed silver particles before grafting the affected tissue has been reported [206].

8.3. Treatment of Argyrosis

Following acute angle-closure glaucoma, the use of Q-S Nd:YAG laser iridotomy in a patient with ocular argyrosis was reported, with each laser shot causing clearance of the argyrotic deposits anterior to the iridotomy site; the procedure was also performed in the contralateral eye as a preventive measure [151]. The cleared cornea areas remained unchanged for at least eight months, the follow-up period.

9. Forensic and Toxicological Aspects

Scarce postmortem evaluations of argyric patients have been reported [31,32,33,40,42,135]. A substantiated link between silver exposure and death was not found, with the patients often having many comorbidities or a clear non-related cause of death [21,31,32,33,40,42,135]. Still, these contributed to strengthening the notion that silver deposition can happen in several organs without leading to any clinically perceived consequences [31,33,40,42,135]. Autopsy findings after silver treatment of burn victims indicate the highest levels occur in the skin, gingiva, cornea, liver, and kidneys [15].
Silver and silver nanoparticles are relatively nontoxic, supporting their wide application [15,16,18,286]. Lesions of the kidneys and lungs and arteriosclerosis have been attributed to both industrial and medicinal exposures [15]. Deposition of silver in renal glomerular basement membranes after high-level exposure may produce hypertension and possible cardiac complications [15,287]. At lower exposure levels, more subtle effects of impaired endothelial function and inhibition of vascular endothelial growth factor action result in impaired angiogenesis and vasorelaxation [287,288]. The respiratory tract may be affected in severe cases of silver intoxication. Chronic bronchitis has also been reported to result from the medicinal use of colloidal silver. Large oral doses of silver nitrate or acetate may cause severe gastrointestinal irritation due to its caustic action [18]. After ingestion of 15 mL of silver nitrate solution, excruciating burning pain in the throat and nostrils was reported, but with the absence of any other symptoms or signs other than a whitish membrane on the oral mucosa, even after upper gastrointestinal endoscopy [289]. It has been reported that levels of AgNP administered i.v. at a dose above 20 mg/kg are toxic [290]. Silver has very limited genotoxic effects and is not considered a carcinogen.

10. Conclusions and Future Perspectives

A precise cut point for silver ingested after which GA development should be expected has not been determined, for which contributes to the rarity of this occurrence but also the unawareness of argyric patients regarding the silver products’ composition and their consumption magnitude [64,200,211,220,221].
Argyria is the staining of tissues following silver accumulation [1,2,4]. It can be categorized as GA or LA, whether silver reaches the afflicted tissue(s) via the systemic bloodstream or local impregnation, respectively [44,70,72]. Furthermore, LA can be classified according to the site of deposition, with the most notorious types being cutaneous localized argyria, ocular argyrosis, and amalgam tattoos [2,97,112]. General major characteristics of argyria are resumed in Figure 7.
In the genesis of argyria development, several silver sources have been identified, which can be divided into three main categories: iatrogenic, occupational, and alternative medicine-related (Table 1). Currently, silver compounds in medicine have been refined, and indications for their use are restrained when compared to the past, being mainly related to the local application for asepsis insurance, wound cautery, and teeth restoration, avoiding systemic exposure [8]. Work conditions have also improved, with the advent of adequate ventilation and proper protective equipment, making the onset of argyria following occupational exposure a much rarer event [8,81]. These, along with hoodwinking marketing, mainly online, responsible for spreading misinformation about silver health benefits and neglecting its potential hazards, have caused an increase in the number of agyria case reports, particularly generalized argyria, with neither medical nor occupational genesis [20,66,89,200,244]. Except for light exposure, which plays an important role in aggravating the pigmentation, other factors besides silver exposition itself, contributing to argyria onset, are not known [48,79,130].
Argyric patients usually present with the absence of signs and symptoms related to argyria. What brings them forth is the aesthetical nuisance, which can lead to significant embarrassment and social withdrawal, even more after realizing that the pigmentation is permanent [9,132,143,223]. To diagnose argyria, physical examination and anamnesis alone can be very accurate, but maximum specificity is only achieved with EDXS of the stained tissue, as it allows ascertainment of silver present in the deposits, as well as quantification of other present nanoparticles [73,74,128,144,146].
Novel treatment modalities, with greater safety and effectivity than those ever achieved with previous techniques, now exist. Q-S 1064 nm Nd:YAG laser and Q-S P 755 nm Alexandrite Laser have shown potential to diametrically change argyria’s prognosis from permanent coloration to the restoration of previous complexion [216,219,223]. Future studies further looking into these techniques can help better clarify the mechanism of pigment resolution, optimize the results, and truly bring renewed hope to argyric patients.

Author Contributions

Conceptualization, R.J.D.-O.; data curation, formal analysis, and writing—original draft preparation, L.M.; writing—review and editing, L.M. and R.J.D.-O.; supervision, R.J.D.-O. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, and royalties.

Institutional Review Board Statement

All procedures were performed according to the ethical and legal standards of the institution.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest. No writing assistance was used in the production of this manuscript.

References

  1. Burgert, J.M. Argyria resulting from chronic use of colloidal silver in a patient presenting for colonoscopy. A&A Pract. 2014, 3, 73–75. [Google Scholar] [CrossRef]
  2. Boix-Vilanova, J.; Del Pozo, L.J.; Martinez, M.; Ramos, D.; Izquierdo, N. Dermoscopy of localised argyria: Apropos of five cases. Australas. J. Dermatol. 2020, 61, e122–e123. [Google Scholar] [CrossRef] [PubMed]
  3. Bingham, E.; Cohrssen, B. Patty’s Toxicology, 6th ed.; Wiley-Blackwell: Hoboken, NJ, USA, 2012. [Google Scholar]
  4. Witkowski, J.A.; Parish, L.C. On being blue: Argyria still exists. Skinmed 2004, 3, 304–305. [Google Scholar] [CrossRef] [PubMed]
  5. Van de Voorde, K.; Nijsten, T.; Schelfhout, K.; Moorkens, G.; Lambert, J. Long-term use of silver containing nose-drops resulting in systemic argyria. Acta Clin. Belg. 2005, 60, 33–35. [Google Scholar] [CrossRef]
  6. Kim, Y.; Suh, H.S.; Cha, H.J.; Kim, S.H.; Jeong, K.S.; Kim, D.H. A case of generalized argyria after ingestion of colloidal silver solution. Am. J. Ind. Med. 2009, 52, 246–250. [Google Scholar] [CrossRef]
  7. Kubba, A.; Kubba, R.; Batrani, M.; Pal, T. Argyria an unrecognized cause of cutaneous pigmentation in Indian patients: A case series and review of the literature. Indian J. Dermatol. Venereol. Leprol. 2013, 79, 805–811. [Google Scholar] [CrossRef]
  8. Sato, S.; Sueki, H.; Nishijima, A. Two unusual cases of argyria: The application of an improved tissue processing method for X-ray microanalysis of selenium and sulphur in silver-laden granules. Br. J. Dermatol. 1999, 140, 158–163. [Google Scholar] [CrossRef]
  9. White, J.M.; Powell, A.M.; Brady, K.; Russell-Jones, R. Severe generalized argyria secondary to ingestion of colloidal silver protein. Clin. Exp. Dermatol. 2003, 28, 254–256. [Google Scholar] [CrossRef]
  10. Lai-Becker, M.W.; Burns, M.M. Silver. In Goldfrank’s Toxicologic Emergencies, 11th ed.; McGraw-Hill Education: New York, NY, USA, 2019. [Google Scholar]
  11. National Center for Biotechnology Information. PubChem Element Summary for Atomic Number 47, Silver; NCBI: Bethesda, MD, USA, 2004. [Google Scholar]
  12. National Center for Biotechnology Information. PubChem Compound Summary for CID 23954, Silver; NCBI: Bethesda, MD, USA, 2004. [Google Scholar]
  13. Drake, P.L.; Hazelwood, K.J. Exposure-related health effects of silver and silver compounds: A review. Ann. Occup. Hyg. 2005, 49, 575–585. [Google Scholar] [CrossRef] [Green Version]
  14. Lee, J.H.; Kwon, M.; Ji, J.H.; Kang, C.S.; Ahn, K.H.; Han, J.H.; Yu, I.J. Exposure assessment of workplaces manufacturing nanosized TiO2 and silver. Inhal. Toxicol. 2011, 23, 226–236. [Google Scholar] [CrossRef]
  15. Hadrup, N.; Lam, H.R. Oral toxicity of silver ions, silver nanoparticles and colloidal silver—A review. Regul. Toxicol. Pharmacol. 2014, 68, 1–7. [Google Scholar] [CrossRef] [PubMed]
  16. World Health Organization. Silver as a Drinking-Water Disinfectant; WHO: Geneva, Switzerland, 2018. [Google Scholar]
  17. Klaassen, C.D. Casarett and Doull’s Toxicology: The Basic Science of Poisons, 9th ed.; McGraw-Hill Education: New York, NY, USA, 2019. [Google Scholar]
  18. Wang, Z.; Xia, T.; Liu, S. Mechanisms of nanosilver-induced toxicological effects: More attention should be paid to its sublethal effects. Nanoscale 2015, 7, 7470–7481. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Fung, M.C.; Bowen, D.L. Silver products for medical indications: Risk-benefit assessment. J. Toxicol. Clin. Toxicol. 1996, 34, 119–126. [Google Scholar] [CrossRef]
  20. Wadhera, A.; Fung, M. Systemic argyria associated with ingestion of colloidal silver. Dermatol. Online J. 2005, 11, 12. [Google Scholar]
  21. Lansdown, A.B. A pharmacological and toxicological profile of silver as an antimicrobial agent in medical devices. Adv. Pharmacol. Sci. 2010, 2010, 910686. [Google Scholar] [CrossRef] [Green Version]
  22. Mayr, M.; Kim, M.J.; Wanner, D.; Helmut, H.; Schroeder, J.; Mihatsch, M.J. Argyria and decreased kidney function: Are silver compounds toxic to the kidney? Am. J. Kidney Dis. 2009, 53, 890–894. [Google Scholar] [CrossRef] [PubMed]
  23. Palamar, M.; Midilli, R.; Egrilmez, S.; Akalin, T.; Yagci, A. Black tears (melanodacryorrhea) from argyrosis. Arch. Ophthalmol. 2010, 128, 503–505. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Lansdown, A.B. Silver in health care: Antimicrobial effects and safety in use. Curr. Probl. Dermatol. 2006, 33, 17–34. [Google Scholar] [CrossRef] [Green Version]
  25. Hanna, C.; Fraunfelder, F.T.; Sanchez, J. Ultrastructural study of argyrosis of the cornea and conjunctiva. Arch. Ophthalmol. 1974, 92, 18–22. [Google Scholar] [CrossRef]
  26. Bleehen, S.S.; Gould, D.J.; Harrington, C.I.; Durrant, T.E.; Slater, D.N.; Underwood, J.C. Occupational argyria; light and electron microscopic studies and X-ray microanalysis. Br. J. Dermatol. 1981, 104, 19–26. [Google Scholar] [CrossRef]
  27. Health and Safety Executive. EH40/2005 Workplace Exposure Limits; HSE: London, UK, 2020. [Google Scholar]
  28. Williams, N. Longitudinal medical surveillance showing lack of progression of argyrosis in a silver refiner. Occup. Med. (Lond.) 1999, 49, 397–399. [Google Scholar] [CrossRef] [Green Version]
  29. Jonas, L.; Bloch, C.; Zimmermann, R.; Stadie, V.; Gross, G.E.; Schäd, S.G. Detection of silver sulfide deposits in the skin of patients with argyria after long-term use of silver-containing drugs. Ultrastruct. Pathol. 2007, 31, 379–384. [Google Scholar] [CrossRef]
  30. Lansdown, A.B. Critical observations on the neurotoxicity of silver. Crit. Rev. Toxicol. 2007, 37, 237–250. [Google Scholar] [CrossRef]
  31. Goebel, H.H.; Muller, J. Ultrastructural observations on silver deposition in the choroid plexus of a patient with argyria. Acta Neuropathol. 1973, 26, 247–251. [Google Scholar] [CrossRef]
  32. Mirsattari, S.M.; Hammond, R.R.; Sharpe, M.D.; Leung, F.Y.; Young, G.B. Myoclonic status epilepticus following repeated oral ingestion of colloidal silver. Neurology 2004, 62, 1408–1410. [Google Scholar] [CrossRef] [PubMed]
  33. Landas, S.; Fischer, J.; Wilkin, L.D.; Mitchell, L.D.; Johnson, A.K.; Turner, J.W.; Theriac, M.; Moore, K.C. Demonstration of regional blood-brain barrier permeability in human brain. Neurosci. Lett. 1985, 57, 251–256. [Google Scholar] [CrossRef]
  34. Bracey, N.A.; Zipursky, J.S.; Juurlink, D.N. Argyria caused by chronic ingestion of silver. Can. Med. Assoc. J. 2018, 190, E139. [Google Scholar] [CrossRef] [Green Version]
  35. DiVincenzo, G.D.; Giordano, C.J.; Schriever, L.S. Biologic monitoring of workers exposed to silver. Int. Arch. Occup. Environ. Health 1985, 56, 207–215. [Google Scholar] [CrossRef]
  36. Sue, Y.M.; Lee, J.Y.; Wang, M.C.; Lin, T.K.; Sung, J.M.; Huang, J.J. Generalized argyria in two chronic hemodialysis patients. Am. J. Kidney Dis. 2001, 37, 1048–1051. [Google Scholar] [CrossRef]
  37. Dijkstra, M.; Havinga, R.; Vonk, R.J.; Kuipers, F. Bile secretion of cadmium, silver, zinc and copper in the rat. Involvement of various transport systems. Life Sci. 1996, 59, 1237–1246. [Google Scholar] [CrossRef]
  38. Kwon, H.B.; Lee, J.H.; Lee, S.H.; Lee, A.Y.; Choi, J.S.; Ahn, Y.S. A case of argyria following colloidal silver ingestion. Ann. Dermatol. 2009, 21, 308–310. [Google Scholar] [CrossRef] [Green Version]
  39. Guenova, E.; Schaller, M. Residents’ corner September 2012. CarpeDIEM—Dermatological indications for electron microscopy: Argyria. Eur. J. Dermatol. 2012, 22, 718. [Google Scholar] [CrossRef] [PubMed]
  40. Gettler, A.O.; Rhoads, C.P.; Weiss, S. A Contribution to the pathology of generalized argyria with a discussion of the fate of silver in the human body. Am. J. Pathol. 1927, 3, 631–652. [Google Scholar]
  41. Rauber, G.; Duprez, A.; Bibas, H. Argyria with hepatic localization. Apropos of a case. Med. Chir. Dig. 1981, 10, 319–320. [Google Scholar]
  42. Dietl, H.W.; Anzil, A.P.; Mehraein, P. Brain involvement in generalized argyria. Clin. Neuropathol. 1984, 3, 32–36. [Google Scholar]
  43. Prescott, R.J.; Wells, S. Systemic argyria. J. Clin. Pathol. 1994, 47, 556–557. [Google Scholar] [CrossRef]
  44. Brandt, D.; Park, B.; Hoang, M.; Jacobe, H.T. Argyria secondary to ingestion of homemade silver solution. J. Am. Acad. Dermatol. 2005, 53, S105–S107. [Google Scholar] [CrossRef] [PubMed]
  45. Chang, A.L.; Khosravi, V.; Egbert, B. A case of argyria after colloidal silver ingestion. J. Cutan. Pathol. 2006, 33, 809–811. [Google Scholar] [CrossRef] [PubMed]
  46. Pezzarossa, E.; Alinovi, A.; Ferrari, C. Generalized argyria. J. Cutan. Pathol. 1983, 10, 361–363. [Google Scholar] [CrossRef]
  47. Tomi, N.S.; Kränke, B.; Aberer, W. A silver man. Lancet 2004, 363, 532. [Google Scholar] [CrossRef]
  48. Bianchi, L.; Orlandi, A.; Di Stefani, A.; Ricci, R.; Chimenti, S. “Familial” generalized argyria. Arch. Dermatol. 2006, 142, 789–790. [Google Scholar] [CrossRef]
  49. Reddy, S.G.; Martin, J.M.t.; Kraus, E.W.; Meffert, J.J. Generalized blue-gray pigmentation—Quiz case. Arch. Dermatol. 2009, 145, 1053–1058. [Google Scholar] [CrossRef]
  50. Park, S.W.; Shin, H.T.; Lee, K.T.; Lee, D.Y. Medical concern for colloidal silver supplementation: Argyria of the nail and face. Ann. Dermatol. 2013, 25, 111–112. [Google Scholar] [CrossRef] [Green Version]
  51. Butzmann, C.M.; Technau-Hafsi, K.; Bross, F. “Silver man” argyria of the skin after ingestion of a colloidal silver solution. J. Dtsch. Dermatol. Ges. 2015, 13, 1030–1032. [Google Scholar] [CrossRef]
  52. Gülseren, D.; Arzberger, E.; Cerroni, L.; Hofmann-Wellenhof, R.; Richtig, E. Reflectance confocal microscopy and dermatopathologic findings of cutaneous argyria after colloidal silver ingestion. J. Eur. Acad. Dermatol. Venereol. 2017, 31, e178–e179. [Google Scholar] [CrossRef] [PubMed]
  53. Wickless, S.C.; Shwayder, T.A. Medical mystery—The answer. N. Engl. J. Med. 2004, 351, 2349–2350. [Google Scholar] [CrossRef]
  54. Osińska, J.; Poborc-Godlewska, J.; Kieć-Swierczyńska, M.; Głuszcz, M. 6 cases of argyria among workers engaged in silverplating radio subunits. Med. Pr. 1982, 33, 361–364. [Google Scholar]
  55. Pariser, R.J. Generalized argyria. Clinicopathologic features and histochemical studies. Arch. Dermatol. 1978, 114, 373–377. [Google Scholar] [CrossRef]
  56. Plack, W.; Bellizzi, R. Generalized argyria secondary to chewing photographic film. Report of a case. Oral Surg. Oral Med. Oral Pathol. 1980, 49, 504–506. [Google Scholar] [CrossRef]
  57. Hanada, K.; Hashimoto, I.; Kon, A.; Kida, K.; Mita, R. Silver in sugar particles and systemic argyria. Lancet 1998, 351, 960. [Google Scholar] [CrossRef]
  58. Molina-Hernandez, A.I.; Diaz-Gonzalez, J.M.; Saeb-Lima, M.; Dominguez-Cherit, J. Argyria after Silver Nitrate Intake: Case Report and Brief Review of Literature. Indian J. Dermatol. 2015, 60, 520. [Google Scholar] [CrossRef]
  59. Jacobs, R. Argyria: My life story. Clin. Dermatol. 2006, 24, 66–69. [Google Scholar] [CrossRef] [PubMed]
  60. Baker, J.W.; Leidy, K.L.; Smith, K.M.; Okeke, U.S. Argyria associated with use of systemic colloidal silver. Fed. Pract. 2011, 28, 39–42. [Google Scholar]
  61. Plewig, G.; Lincke, H.; Wolff, H.H. Silver-blue nails. Acta Derm. Venereol. 1977, 57, 413–419. [Google Scholar]
  62. McKenna, J.K.; Hull, C.M.; Zone, J.J. Argyria associated with colloidal silver supplementation. Int. J. Dermatol. 2003, 42, 549. [Google Scholar] [CrossRef] [PubMed]
  63. Gottesman, S.P.; Goldberg, G.N. Immediate successful treatment of argyria with a single pass of multiple Q-switched laser wavelengths. JAMA Dermatol. 2013, 149, 623–624. [Google Scholar] [CrossRef]
  64. Lencastre, A.; Lobo, M.; João, A. Argyria—Case report. An. Bras. Dermatol. 2013, 88, 413–416. [Google Scholar] [CrossRef] [Green Version]
  65. Cinotti, E.; Labeille, B.; Douchet, C.; Cambazard, F.; Perrot, J.L. Dermoscopy, reflectance confocal microscopy, and high-definition optical coherence tomography in the diagnosis of generalized argyria. J. Am. Acad. Dermatol. 2017, 76, S66–S68. [Google Scholar] [CrossRef]
  66. Rodriguez, V.; Romaguera, R.L.; Heidecker, B. Silver-Containing Wound Cream Leading to Argyria-Always Ask About Alternative Health Products. Am. J. Med. 2017, 130, e145–e146. [Google Scholar] [CrossRef] [Green Version]
  67. Fox, J.D.; Baker, J.A.; Tosti, A. Chromonychia in an Asymptomatic Vitamin Consumer. Ski. Appendage Disord. 2016, 1, 131–133. [Google Scholar] [CrossRef] [Green Version]
  68. Kalouche, H.; Watson, A.; Routley, D. Blue lunulae: Argyria and hypercopprecaemia. Australas. J. Dermatol. 2007, 48, 182–184. [Google Scholar] [CrossRef]
  69. Merchant, F.; Carpenter, T. Blue-gray discoloration of the skin. Am. Fam. Physician 2011, 84, 821–822. [Google Scholar]
  70. Ellison, D.W.; Chant, A.D.; Harrison, T.A.; Theaker, J.M. Localized argyria: A complication of the repair of inguinal hernia with silver filigree. Br. J. Surg. 1993, 80, 1325. [Google Scholar] [CrossRef] [PubMed]
  71. Enei, M.L.; Paschoal, F.M.; Valdés, R. Argyria mimicking a blue nevis: Dermoscopy features. An. Bras. Dermatol. 2013, 88, 452–455. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Beutler, B.D.; Lee, R.A.; Cohen, P.R. Localized cutaneous argyria: Report of two patients and literature review. Dermatol. Online J. 2016, 22, 11. [Google Scholar]
  73. Nagano, T.; Oka, M.; Horikawa, T.; Nishigori, C.; Kotera, M. Single, blue nevus-like localized argyria. J. Dermatol. 2016, 43, 1359–1360. [Google Scholar] [CrossRef] [PubMed]
  74. Friedmann, D.P.; Buckley, S.; Mishra, V. Localized cutaneous argyria from a nasal piercing successfully treated with a Picosecond 755-nm Q-Switched Alexandrite Laser. Dermatol. Surg. 2017, 43, 1094–1095. [Google Scholar] [CrossRef] [PubMed]
  75. Isak, V.; Beerli, T.; Cozzio, A.; Flatz, L. A Rare Case of Localized Argyria on the Face. Case Rep. Dermatol. 2019, 11, 23–27. [Google Scholar] [CrossRef]
  76. Robinson-Bostom, L.; Pomerantz, D.; Wilkel, C.; Mader, R.; Lerner, L.; Dufresne, R.; Flotte, T. Localized argyria with pseudo-ochronosis. J. Am. Acad. Dermatol. 2002, 46, 222–227. [Google Scholar] [CrossRef]
  77. Buckley, W.R. Localized argyria. Arch. Dermatol. 1963, 88, 531–539. [Google Scholar] [CrossRef]
  78. Buckley, W.R.; Oster, C.F.; Fassett, D.W. Localized argyria, II. Chemical nature of the silver containing particles. Arch. Dermatol. 1965, 92, 697–705. [Google Scholar] [CrossRef] [PubMed]
  79. Granstein, R.D.; Sober, A.J. Drug and heavy metal-induced hyperpigmentation. J. Am. Acad. Dermatol. 1981, 5, 1–18. [Google Scholar] [CrossRef]
  80. Rongioletti, F.; Robert, E.; Buffa, P.; Bertagno, R.; Rebora, A. Blue nevi-like dotted occupational argyria. J. Am. Acad. Dermatol. 1992, 27, 1015–1016. [Google Scholar] [CrossRef]
  81. Kapur, N.; Landon, G.; Yu, R.C. Localized argyria in an antique restorer. Br. J. Dermatol. 2001, 144, 191–192. [Google Scholar] [CrossRef] [PubMed]
  82. Sendagorta, E.; Herranz, P.; Casado, B.; Gómez, C.; Ramírez, P.; Feito, M.; García-Cabezas, M.A. Scattered blue maculae in a patient with albinism. Clin. Exp. Dermatol. 2011, 36, 419–420. [Google Scholar] [CrossRef]
  83. Kwon, I.H.; Ahn, H.H.; Ryu, H.J.; Rhyu, I.J. Sudden appearance of black macules on palmar aspect of two university chemistry students. Int. J. Dermatol. 2016, 55, e167–e169. [Google Scholar] [CrossRef]
  84. Fisher, N.M.; Marsh, E.; Lazova, R. Scar-localized argyria secondary to silver sulfadiazine cream. J. Am. Acad. Dermatol. 2003, 49, 730–732. [Google Scholar] [CrossRef]
  85. Schwieger-Briel, A.; Kiritsi, D.; Schumann, H.; Meiss, F.; Technau, K.; Bruckner-Tuderman, L. Grey spots in a patient with dystrophic epidermolysis bullosa. Br. J. Dermatol. 2010, 163, 1124–1126. [Google Scholar] [CrossRef]
  86. Rumayor Piña, A.; Martínez Martínez, M.; Toral Rizo, V.H.; Ajudarte Lopes, M.; Paes de Almeida, O. Cutaneous amalgam tattoo in a dental professional: An unreported occupational argyria. Br. J. Dermatol. 2012, 167, 1184–1185. [Google Scholar] [CrossRef]
  87. Garcias-Ladaria, J.; Hernandez-Bel, P.; Torregrosa-Calatayud, J.L.; Martínez-Aparicio, A. Localized cutaneous argyria: A report of 2 cases. Actas Dermo. Sifiliogr. 2013, 104, 253–254. [Google Scholar] [CrossRef]
  88. Al-Niaimi, F. Localized argyria from silver nasal piercing unresponsive to Q-switched laser successfully treated with a 1064 picoseconds laser. J. Cosmet. Dermatol. 2020, 19, 1535–1536. [Google Scholar] [CrossRef]
  89. Park, M.Y.; Lee, J.S.; Jin, H.J.; You, H.S.; Kim, G.W.; Ko, H.C.; Kim, B.S.; Kim, M.B.; Kim, H.S. Localized argyria: Troublesome side-effect of acupuncture. J. Eur. Acad. Dermatol. Venereol. JEADV 2018, 32, e62–e65. [Google Scholar] [CrossRef]
  90. Karakasli, A.; Hapa, O.; Akdeniz, O.; Havitcioğlu, H. Dermal argyria: Cutaneous manifestation of a megaprosthesis for distal femoral osteosarcoma. Indian J. Orthop. 2014, 48, 326–328. [Google Scholar] [CrossRef] [PubMed]
  91. Dummett, C.O. Systemic significance of oral pigmentation and discoloration. Postgrad. Med. 1971, 49, 78–82. [Google Scholar] [CrossRef] [PubMed]
  92. Buchner, A. Amalgam tattoo (amalgam pigmentation) of the oral mucosa: Clinical manifestations, diagnosis and treatment. Refuat Hapeh Vehashinayim (1993) 2004, 21, 25–28. [Google Scholar]
  93. Wu, Q.; Yang, Z.; Su, L. Light microscope and energy dispersive X-ray analysis of amalgam pigmentation. Zhonghua Kou Qiang Yi Xue Za Zhi 1995, 30, 140–142. [Google Scholar] [PubMed]
  94. Bell, C.D.; Cooksey, D.E.; Nickel, W.R. Amalgam tattoo (localized argyria). Arch. Derm. 1952, 66, 523–525. [Google Scholar] [CrossRef]
  95. Dubach, P.; Caversaccio, M. Images in clinical medicine. Amalgam tattoo. N. Engl. J. Med. 2011, 364, e29. [Google Scholar] [CrossRef] [Green Version]
  96. Kirchoff, D.A. Localized argyria after a surgical endodontic procedure. Report of a case. Oral Surg. Oral Med. Oral Pathol. 1971, 32, 613–617. [Google Scholar] [CrossRef]
  97. Kehoe, J.C. Intracanal corrosion of a silver cone producing a localized argyria: Scanning electron microscope and energy dispersive X-ray analyzer analyses. J. Endod. 1984, 10, 199–201. [Google Scholar] [CrossRef]
  98. Matsumura, T.; Kumakiri, M.; Ohkawara, A.; Himeno, H.; Numata, T.; Adachi, R. Detection of selenium in generalized and localized argyria: Report of four cases with X-ray microanalysis. J. Dermatol. 1992, 19, 87–93. [Google Scholar] [CrossRef] [PubMed]
  99. Weathers, D.R.; Fine, R.M. Amalgam tattoo of oral mucosa. Arch. Dermatol. 1974, 110, 727–728. [Google Scholar] [CrossRef] [PubMed]
  100. Aoyagi, H.; Katagiri, M. Long-term effects of Ag-containing alloys on mucous tissue present in biopsy samples. Dent. Mater. J. 2004, 23, 340–347. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  101. Ferrara, G.; Filosa, A.; Mariani, M.P.; Fasanella, L. Occupational Argyria of the Nasal Mucosa. Head Neck Pathol. 2018, 12, 252–254. [Google Scholar] [CrossRef] [PubMed]
  102. Güemes-Villahoz, N.; Burgos-Blasco, B.; CasoViesca, A.; Benitez-Del-Castillo, J.M. Non invasive methods to diagnose ocular argyrosis. J. Fr. Ophtalmol. 2020, 43, e185–e187. [Google Scholar] [CrossRef] [PubMed]
  103. Secretan, J.P.; Demontmollin, D. Several cases of industrial argyrosis of the rhino-bronchial mucous membranes. Pract. Otorhinolaryngol. (Basel) 1965, 27, 167–171. [Google Scholar]
  104. Liakhovitskiĭ, N.S. Argyria of the urethra. Urol. Nefrol. (Mosk.) 1968, 33, 59–61. [Google Scholar]
  105. Gordon, D.H.; Singla, S.K.; Goode, R.; Pollack, H.M.; Glanz, S. Argyrosis of the urinary tract. Am. J. Roentgenol. 1981, 136, 423–426. [Google Scholar] [CrossRef]
  106. Matzinger, M.A.; Gray, R.R.; Leekam, R.N.; Grosman, H.; St Louis, E.L. Argyrosis of the urinary tract. J. Clin. Ultrasound 1985, 13, 288–290. [Google Scholar] [CrossRef]
  107. Kojima, Y.; Uchida, K.; Takiuchi, H.; Wakatsuki, A.; Sakurai, T.; Fujita, Y.; Shirai, D.; Kobayashi, Y. Argyrosis of the urinary tract after silver nitrate instillation: Report of a case. Hinyokika Kiyo 1993, 39, 41–44. [Google Scholar]
  108. Thomas, K.; Sproston, A.R.; Kingsland, C.R. A case of vaginal argyrosis: All that glistens isn’t gold. BJOG Int. J. Obstet. Gynaecol. 2001, 108, 890–891. [Google Scholar] [CrossRef] [PubMed]
  109. Griffiths, M.R.; Milne, J.T.; Porter, W.M. Penile argyria. Br. J. Dermatol. 2006, 155, 1074–1075. [Google Scholar] [CrossRef] [PubMed]
  110. Hall, B.J.; Cockerell, C.J.; Chisholm, C.; Vandergriff, T.; Jessup, C.; Motaparthi, K.; Elston, D.M. Amalgam Tattoo. In Diagnostic Pathology: Nonneoplastic Dermatopathology, 2nd ed.; Elsevier: Amsterdam, The Netherlands, 2017. [Google Scholar]
  111. Madi, H.A.; Steel, D.H.W.; Kotagiri, A.K. Multimodal imaging in a patient with ocular argyrosis complicated by diabetic retinopathy. Can. J. Ophthalmol. 2018, 53, e262–e266. [Google Scholar] [CrossRef] [Green Version]
  112. Jensen, S.F. Argyrosis of conjunctiva in studio photographer. Acta Ophthalmol. (Copenh.) 1962, 40, 544–547. [Google Scholar] [CrossRef]
  113. Hodson, T.J.; Gillies, W.E. Argyrol, argyrosis and the acquisition of art. Aust. N. Z. J. Ophthalmol. 1985, 13, 391–394. [Google Scholar] [CrossRef] [PubMed]
  114. Couto, A., Jr.; Molles, S.; Simionato, R.; Kamlot, D. Eye’s and excretory lacrimal apparatus’ argyrosis: Case report. Arq. Bras. Oftalmol. 2009, 72, 836–838. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  115. Weiler, H.H.; Lemp, M.A.; Zeavin, B.H.; Suarez, A.F. Argyria of the cornea due to self-administration of eyelash dye. Ann. Ophthalmol. 1982, 14, 822–823. [Google Scholar] [PubMed]
  116. Karcioglu, Z.A.; Caldwell, D.R. Corneal argyrosis: Histologic, ultrastructural and microanalytic study. Can. J. Ophthalmol. 1985, 20, 257–260. [Google Scholar] [PubMed]
  117. Pala, G.; Fronterré, A.; Scafa, F.; Scelsi, M.; Ceccuzzi, R.; Gentile, E.; Candura, S.M. Ocular argyrosis in a silver craftsman. J. Occup. Health 2008, 50, 521–524. [Google Scholar] [CrossRef] [Green Version]
  118. Sánchez-Pulgarín, M.; Matilla, M.; Martinez-de-la-Casa, J.M.; Jerez, M.; Benítez-del-Castillo, J.M. Confocal microscopy in ocular argyrosis. Cornea 2010, 29, 580–582. [Google Scholar] [CrossRef] [PubMed]
  119. Tendler, I.; Pulitzer, M.P.; Roggli, V.; Abramson, D.H.; Marr, B.P. Ocular argyrosis mimicking conjunctival melanoma. Cornea 2017, 36, 747–748. [Google Scholar] [CrossRef] [PubMed]
  120. Gutman, F.A.; Crosswell, H.H., Jr. Argyrosis of the cornea without clinical conjunctival involvement. Am. J. Ophthalmol. 1968, 65, 183–187. [Google Scholar] [CrossRef]
  121. Wu, M.; Wang, X.; Shao, T.; Wang, Y. Case Report: In vivo confocal microscopic appearance of corneal argyrosis. Optom. Vis. Sci. 2017, 94, 1066–1069. [Google Scholar] [CrossRef] [PubMed]
  122. Scroggs, M.W.; Lewis, J.S.; Proia, A.D. Corneal argyrosis associated with silver soldering. Cornea 1992, 11, 264–269. [Google Scholar] [CrossRef] [PubMed]
  123. Texas Tech University Health Sciences Center. List Eye Atlas Contributors. SOM Ophthalmology Eye Atlas: Conjunctiva. 2021. Available online: https://www.ttuhsc.edu/medicine/ophthalmology/eye-atlas/conjunctiva.aspx (accessed on 12 April 2021).
  124. Leite, C.M.; Botelho, A.S.; Oliveira, J.R.; Cardoso, S.V.; Loyola, A.M.; Gomez, R.S.; Vaz, R.R. Immunolocalization of HLA-DR and metallothionein on amalgam tattoos. Braz. Dent. J. 2004, 15, 99–103. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  125. Amber, K.T.; Winslow, C.Y.; Styperek, A.; Schwartz, P.H.; Shiman, M.I.; Elgart, G. Blue skin. Int. J. Dermatol. 2014, 53, 275–276. [Google Scholar] [CrossRef] [PubMed]
  126. East, B.W.; Boddy, K.; Williams, E.D.; Macintyre, D.; McLay, A.L. Silver retention, total body silver and tissue silver concentrations in argyria associated with exposure to an anti-smoking remedy containing silver acetate. Clin. Exp. Dermatol. 1980, 5, 305–311. [Google Scholar] [CrossRef]
  127. Aaseth, J.; Olsen, A.; Halse, J.; Hovig, T. Argyria-tissue deposition of silver as selenide. Scand. J. Clin. Lab. Investig. 1981, 41, 247–251. [Google Scholar] [CrossRef]
  128. Westhofen, M.; Schäfer, H. Generalized argyrosis in man: Neurotological, ultrastructural and X-ray microanalytical findings. Arch. Otorhinolaryngol. 1986, 243, 260–264. [Google Scholar] [CrossRef]
  129. Peterson, W.C., Jr. Argyria. Minn. Med. 1968, 51, 533–534. [Google Scholar]
  130. Shelley, W.B.; Shelley, E.D.; Burmeister, V. Argyria: The intradermal “photograph”, a manifestation of passive photosensitivity. J. Am. Acad. Dermatol. 1987, 16, 211–217. [Google Scholar] [CrossRef]
  131. Marshall, J.P., 2nd; Schneider, R.P. Systemic argyria secondary to topical silver nitrate. Arch. Dermatol. 1977, 113, 1077–1079. [Google Scholar] [CrossRef] [PubMed]
  132. Massi, D.; Santucci, M. Human generalized argyria: A submicroscopic and X-ray spectroscopic study. Ultrastruct. Pathol. 1998, 22, 47–53. [Google Scholar] [CrossRef] [PubMed]
  133. García-Martínez, P.; López Aventín, D.; Segura, S.; Gómez-Martín, I.; Lloreta, J.; Ibáñez, J.; Elvira, J.J.; Pujol, R.M. In vivo reflectance confocal microscopy characterization of silver deposits in localized cutaneous argyria. Br. J. Dermatol. 2016, 175, 1052–1055. [Google Scholar] [CrossRef]
  134. Rich, L.L.; Epinette, W.W.; Nasser, W.K. Argyria presenting as cyanotic heart disease. Am. J. Cardiol. 1972, 30, 290–292. [Google Scholar] [CrossRef]
  135. Steininger, H.; Langer, E.; Stömmer, P. Generalized argyrosis. Dtsch. Med. Wochenschr. 1990, 115, 657–662. [Google Scholar] [CrossRef]
  136. Reymond, J.L.; Stoebner, P.; Amblard, P. Cutaneous argyria: An electron microscopic study of four eases with microanalysis X study of one case (author’s transl). Ann. Dermatol. Venereol. 1980, 107, 251–255. [Google Scholar]
  137. Shall, L.; Stevens, A.; Millard, L.G. An unusual case of acquired localized argyria. Br. J. Dermatol. 1990, 123, 403–407. [Google Scholar] [CrossRef]
  138. Wootton, C.I.; May, T.; Khan, M.; Walker, S.L. A pigmented lesion on the earlobe. Clin. Exp. Dermatol. 2015, 40, 457–459. [Google Scholar] [CrossRef]
  139. Arunkajohnsak, S.; Thanomkitti, K.; Kasemsarn, P.; Pattanaprichakul, P.; Jiamton, S.; Eimpunth, S. Successful treatment of acupuncture-induced argyria using Q-switched 1064-nm Nd:YAG laser. JAAD Case Rep. 2020, 6, 984–987. [Google Scholar] [CrossRef]
  140. Tanita, Y.; Kato, T.; Hanada, K.; Tagami, H. Blue macules of localized argyria caused by implanted acupuncture needles. Electron microscopy and roentgenographic microanalysis of deposited metal. Arch. Dermatol. 1985, 121, 1550–1552. [Google Scholar] [CrossRef] [PubMed]
  141. Lee, S.M.; Lee, S.H. Generalized argyria after habitual use of AgNO3. J. Dermatol. 1994, 21, 50–53. [Google Scholar] [CrossRef]
  142. Saager, R.B.; Hassan, K.M.; Kondru, C.; Durkin, A.J.; Kelly, K.M. Quantitative near infrared spectroscopic analysis of Q-Switched Nd:YAG treatment of generalized argyria. Lasers Surg. Med. 2013, 45, 15–21. [Google Scholar] [CrossRef] [Green Version]
  143. Pinto-Almeida, T.; Lobo, I.; Selores, M. Unknown: Bluish-gray macules on the hands of a healthy 34 year old man. Dermatol. Online J. 2013, 19, 18964. [Google Scholar]
  144. Sakai, N.; Aoki, M.; Miyazawa, S.; Akita, M.; Takezaki, S.; Kawana, S. A case of generalized argyria caused by the use of silver protein as a disinfection medicine. Acta Derm. Venereol. 2007, 87, 186–187. [Google Scholar] [CrossRef] [Green Version]
  145. Devins, K.M.; Mogavero, H.S., Jr.; Helm, T.N. Localized argyria with pseudo-ochronosis. Cutis 2015, 95, 29–31. [Google Scholar] [PubMed]
  146. Landas, S.; Bonsib, S.M.; Ellerbroek, R.; Fischer, J. Argyria: Microanalytic-morphologic correlation using paraffin-embedded tissue. Ultrastruct. Pathol. 1986, 10, 129–135. [Google Scholar] [CrossRef] [PubMed]
  147. Greene, R.M.; Su, W.P. Argyria. Am. Fam. Physician 1987, 36, 151–154. [Google Scholar]
  148. González-Serva, A. Normal nail anatomy, normal nail histology, and common reaction patterns. In Scher and Daniel’s Nails: Diagnosis, Surgery, Therapy, 4th ed.; Rubin, A.I., Jellinek, N.J., Daniel, C.R., Scher, R.K., Eds.; Springer: Cham, Switzerland, 2018. [Google Scholar]
  149. Dudeja, L.; Dudeja, I.; Janakiraman, A.; Babu, M. Ocular argyrosis: A case with silver deposits in cornea and lens. Indian J. Ophthalmol. 2019, 67, 267–268. [Google Scholar] [CrossRef]
  150. Panigrahi, A.K.; Aruljothi, L.; Prajna, V.N. Argyrosis. Ophthalmology 2017, 124, 1270. [Google Scholar] [CrossRef]
  151. Geyer, O.; Rothkoff, L.; Lazar, M. Clearing of corneal argyrosis by YAG laser. Br. J. Ophthalmol. 1989, 73, 1009–1010. [Google Scholar] [CrossRef]
  152. Zografos, L.; Uffer, S.; Chamot, L. Unilateral conjunctival-corneal argyrosis simulating conjunctival melanoma. Arch. Ophthalmol. 2003, 121, 1483–1487. [Google Scholar] [CrossRef] [Green Version]
  153. Yanoff, M.; Scheie, H.G. Argyrosis of the conjunctiva and lacrimal sac. Arch. Ophthalmol. 1964, 72, 57–58. [Google Scholar] [CrossRef] [PubMed]
  154. Loeffler, K.U.; Lee, W.R. Argyrosis of the lacrimal sac. Graefe’s Arch. Clin. Exp. Ophthalmol. 1987, 225, 146–150. [Google Scholar] [CrossRef] [PubMed]
  155. Calmettes; Deodati; Amalric. Argyrosis of the crystalline lens. Bull. Soc. Ophtalmol. Fr. 1957, 7–8, 534–535. [Google Scholar]
  156. Stafeeva, K.; Erlanger, M.; Velez-Montoya, R.; Olson, J.L. Ocular argyrosis secondary to long-term ingestion of silver nitrate salts. Clin. Ophthalmol. (Auckl. N. Z.) 2012, 6, 2033–2036. [Google Scholar] [CrossRef] [Green Version]
  157. Sarnat-Kucharczyk, M.; Pojda-Wilczek, D.; Mrukwa-Kominek, E. Diagnostic methods in ocular argyrosis: Case report. Doc. Ophthalmol. 2016, 133, 129–138. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  158. Rahimy, E.; Beardsley, R.; Ferrucci, S.; Ilsen, P.; Sarraf, D. Optical coherence tomography findings in ocular argyrosis. Ophthalmic Surg. Lasers Imaging Retin. 2013, 44, E20–E22. [Google Scholar] [CrossRef]
  159. Kamath, Y.; Sinha, A. Ocular argyrosis in a jeweller. BMJ Case Rep. 2013, 2013. [Google Scholar] [CrossRef] [Green Version]
  160. Bartley, G.B.; Buller, C.R.; Campbell, R.J.; Bullock, J.D. Pigmented episcleral mass from argyrosis following strabismus surgery. Arch. Ophthalmol. 1991, 109, 775–776. [Google Scholar] [CrossRef]
  161. Frei, J.; Schröder, B.; Messerli, J.; Probst, A.; Meyer, P. Localized argyrosis 58 years after strabismus operation—An ophthalmological rarity. Klin. Mon. Augenheilkd. 2001, 218, 61–63. [Google Scholar] [CrossRef]
  162. Moss, A.P.; Sugar, A.; Hargett, N.A.; Atkin, A.; Wolkstein, M.; Rosenman, K.D. The ocular manifestations and functional effects of occupational argyrosis. Arch. Ophthalmol. 1979, 97, 906–908. [Google Scholar] [CrossRef] [PubMed]
  163. Sánchez-Huerta, V.; De Wit-Carter, G.; Hernández-Quintela, E.; Naranjo-Tackman, R. Occupational corneal argyrosis in art silver solderers. Cornea 2003, 22, 604–611. [Google Scholar] [CrossRef]
  164. McClain, C.M.; Kantrow, S.M.; Abraham, J.L.; Price, J.; Parker, E.R.; Robbins, J.B. Localized cutaneous argyria: Two case reports and clinicopathologic review. Am. J. Dermatopathol. 2013, 35, e115–e118. [Google Scholar] [CrossRef]
  165. Sugden, P.; Azad, S.; Erdmann, M. Argyria caused by an earring. Br. J. Plast. Surg. 2001, 54, 252–253. [Google Scholar] [CrossRef] [PubMed]
  166. Pardo-Peret, P.; Sans-Sabrafen, J.; Boleda Relats, M. Argyriasis. Report of a case (author’s transl). Med. Clin. (Barc.) 1979, 73, 386–388. [Google Scholar] [PubMed]
  167. Weber, F.P.; Norman, R.H. Argyria. Proc. R. Soc. Med. 1910, 3, 75–76. [Google Scholar]
  168. Davis, H. Two Cases of Pigmentation: (1) Argyria; (2) Pigmentation of Unknown Origin. Proc. R. Soc. Med. 1926, 20, 92. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  169. Smith, M.D.; Watson, W.C. Argyria: Report of two cases. Glasg. Med. J. 1954, 35, 25–26. [Google Scholar]
  170. Kamalova, S.I.; Khamidullin, Z.G. Argyria as a result of the treatment of stomach ulcers with silver nitrate. Kazan Med. J. 1963, 3, 68–69. [Google Scholar]
  171. Eturska, M.; Obreshkova, E. Argyria in the prolonged use of adsorgan. Vutreshni Boles. 1979, 18, 121–123. [Google Scholar]
  172. Starzyńska, T.; Mandat, A. A case of argyria after peroral treatment of peptic ulcer with silver albuminate. Wiad. Lek. 1987, 40, 691–693. [Google Scholar] [PubMed]
  173. Mittag, H.; Knecht, J.; Arnold, R.; Hüttich, C.; Rupec, M. Argyria. A clinical, chemical analytic and micromorphologic study. Hautarzt 1987, 38, 670–677. [Google Scholar] [PubMed]
  174. Müller, M.; Wiedmann, K.H. Generalized argyria caused by targesin-containing drug used for stomach complaints. Med. Klin. (Munich) 1991, 86, 432–434. [Google Scholar] [PubMed]
  175. Harrison, G.A. Section of skin from case of pigmentation (argyria). Proc. R. Soc. Med. 1924, 17, 5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  176. Adamson, H.G. Case of Trade Argyria. Proc. R. Soc. Med. 1924, 17, 8. [Google Scholar] [CrossRef] [Green Version]
  177. Bristol Medico Chirurgical Society. Argyria from the use of nasal drops. Bristol Med. Chir. J. (1883) 1952, 69, 143–144. [Google Scholar]
  178. Smith, S.Z.; Scheen, S.R.; Allen, J.D., Jr.; Arnn, E.T. Argyria. Arch. Dermatol. 1981, 117, 595–596. [Google Scholar] [CrossRef]
  179. Ondrasik, R.M.; Jordan, P.; Sriharan, A. A clinical mimicker of melanoma with distinctive histopathology: Topical silver nitrate exposure. J. Cutan. Pathol. 2020, 47, 1205–1210. [Google Scholar] [CrossRef]
  180. Wan, A.T.; Conyers, R.A.; Coombs, C.J.; Masterton, J.P. Determination of silver in blood, urine, and tissues of volunteers and burn patients. Clin. Chem. 1991, 37, 1683–1687. [Google Scholar] [CrossRef]
  181. Chaby, G.; Viseux, V.; Poulain, J.F.; De Cagny, B.; Denoeux, J.P.; Lok, C. Topical silver sulfadiazine-induced acute renal failure. Ann. Dermatol. Venereol. 2005, 132, 891–893. [Google Scholar] [CrossRef]
  182. Trop, M.; Novak, M.; Rodl, S.; Hellbom, B.; Kroell, W.; Goessler, W. Silver-coated dressing acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. J. Trauma 2006, 60, 648–652. [Google Scholar] [CrossRef] [PubMed]
  183. Payne, C.M.; Bladin, C.; Colchester, A.C.; Bland, J.; Lapworth, R.; Lane, D. Argyria from excessive use of topical silver sulphadiazine. Lancet 1992, 340, 126. [Google Scholar] [CrossRef]
  184. Maitre, S.; Jaber, K.; Perrot, J.L.; Guy, C.; Cambazard, F. Increased serum and urinary levels of silver during treatment with topical silver sulfadiazine. Ann. Dermatol. Venereol. 2002, 129, 217–219. [Google Scholar]
  185. Silver, S. Bacterial silver resistance: Molecular biology and uses and misuses of silver compounds. FEMS Microbiol. Rev. 2003, 27, 341–353. [Google Scholar] [CrossRef] [Green Version]
  186. Sataline, L. Tarnished silver. Lancet 2004, 363, 1166. [Google Scholar] [CrossRef]
  187. Utikal, J.; Thoelke, A.; Becker, J.C.; Figl, R.; Goerdt, S.; Schadendorf, D.; Ugurel, S. Local cutaneous argyria mimicking melanoma metastases in a patient with disseminated melanoma. J. Am. Acad. Dermatol. 2006, 55, S92–S94. [Google Scholar] [CrossRef]
  188. Holck, D.E.; Klintworth, G.K.; Dutton, J.J.; Foulks, G.N.; Manning, F.J. Localized conjunctival argyrosis: A late sequela of strabismus surgery. Ophthalmic Surg. Lasers 2000, 31, 495–498. [Google Scholar] [CrossRef]
  189. Marner, E. Case of severe argyria after eye treatment with argyrol. Ugeskr. Laeger 1953, 115, 1061–1062. [Google Scholar]
  190. Nielsen, I.O.; Kjaerbo, E. Generalized argyria due to the use of eyedrops containing silver nitrate. Ugeskr. Laeger 1989, 151, 33–34. [Google Scholar]
  191. Capoen, S.C.; Boullie, M.C.; Mallet, E. Argyria in children. Arch. Fr. Pediatr. 1989, 46, 49–50. [Google Scholar]
  192. Jurecka, W. Generalized argyrosis. Hautarzt 1986, 37, 628–631. [Google Scholar] [PubMed]
  193. Konecný, L.; Skerík, P.; Pitha, J. General argyrosis following esophagitis therapy. Ceskoslovenska Otolaryngol. 1966, 15, 101–104. [Google Scholar]
  194. Marie, J.; Léveque, B.; Watchi, J.M.; Desbois, J.C.; Feingold, J. Argyria in a child following pharyngeal sprays of silver salts repeated for 6 years. Ann. Pediatr. (Paris) 1966, 13, 2657–2659. [Google Scholar]
  195. Ohbo, Y.; Fukuzako, H.; Takeuchi, K.; Takigawa, M. Argyria and convulsive seizures caused by ingestion of silver in a patient with schizophrenia. Psychiatry Clin. Neurosci. 1996, 50, 89–90. [Google Scholar] [CrossRef]
  196. Shelton, D.; Goulding, R. Silver poisoning associated with an antismoking lozenge. Br. Med. J. 1979, 1, 267. [Google Scholar] [CrossRef] [Green Version]
  197. Macintire, D.; McLay, A.L.; East, B.W.; Williams, E.D.; Boddy, K. Silver poisoning associated with an antismoking lozenge. Br. Med. J. 1978, 2, 1749–1750. [Google Scholar] [CrossRef] [Green Version]
  198. Van Garsse, L.; Versieck, J. General argyria caused by administration of tobacco-withdrawal tablets containing silver acetate. Ned. Tijdschr. Geneeskd. 1995, 139, 2658–2661. [Google Scholar]
  199. Hau, S.C.; Tuft, S.J. Presumed corneal argyrosis from occlusive soft contact lenses: A case report. Cornea 2009, 28, 703–705. [Google Scholar] [CrossRef]
  200. Bouts, B.A. Images in clinical medicine. Argyria. N. Engl. J. Med. 1999, 340, 1554. [Google Scholar] [CrossRef]
  201. Fisher, R.L.; Zukerman, M. Argyrosis following prolonged intranasal medication with argyrol. J. Mich. State Med. Soc. 1948, 47, 1229. [Google Scholar] [PubMed]
  202. Voldrich, Z.; Holub, M.; Plhoñ, F. Isolated case of general argyrosis after long-term administration of targesine nasal drops. Ceskoslovenska Otolaryngol. 1975, 24, 374–376. [Google Scholar]
  203. Harman, R.R. Argyria. Br. J. Dermatol. 1977, 97 (Suppl. S15), 60. [Google Scholar] [CrossRef]
  204. Akimov, V.N. Argyria caused by uncontrolled use of silver protein in vasomotor rhinitis. Vestnik Otorinolaringol. 1980, 6, 77–78. [Google Scholar]
  205. Raimondo, L.; Garzaro, M.; Molinaro, L.; Bartoli, C.; Provenzano, E.; Pecorari, G. Iatrogenic rhinopharyngeal isolated argyria induced by silver-containing nasal drug. J. Craniofacial Surg. 2014, 25, e149–e151. [Google Scholar] [CrossRef] [PubMed]
  206. Rusch-Behrend, G.D.; Gutmann, J.L. Management of diffuse tissue argyria subsequent to endodontic therapy: Report of a case. Quintessence Int. 1995, 26, 553–557. [Google Scholar] [PubMed]
  207. Kissel, S.O.; Hanratty, J.J. Periodontal treatment of an amalgam tattoo. Compend. Contin. Educ. Dent. 2002, 23, 930–932. [Google Scholar]
  208. D’Haeseleire, P.; Thielens, P.; Bourgois, F.; Vanclooster, R. Are Ag-points, gutta percha and amalgam still applicable for apical sealing? Acta Stomatol. Belg. 1989, 86, 243–250. [Google Scholar]
  209. Schmalz, G.; Garhammer, P. Biological interactions of dental cast alloys with oral tissues. Dent. Mater. 2002, 18, 396–406. [Google Scholar] [CrossRef]
  210. Shimamoto, Y.; Shimamoto, H. Systemic argyria secondary to breath freshener “Jintan Silver Pills”. Hiroshima J. Med. Sci. 1987, 36, 245–247. [Google Scholar]
  211. Thompson, R.; Elliott, V.; Mondry, A. Argyria: Permanent skin discoloration following protracted colloid silver ingestion. BMJ Case Rep. 2009, 2009. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  212. Chung, I.S.; Lee, M.Y.; Shin, D.H.; Jung, H.R. Three systemic argyria cases after ingestion of colloidal silver solution. Int. J. Dermatol. 2010, 49, 1175–1177. [Google Scholar] [CrossRef] [PubMed]
  213. Krejci-Manwaring, J.; West, D.A.; Aires, D.J. What is your diagnosis? Argyria. Cutis 2013, 91, 233–234. [Google Scholar]
  214. Chhabra, L.; Sareen, P.; Trivedi, N. The silver man: A rare cosmetic complication of alternative medicine. BMJ Case Rep. 2013, 2013. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  215. Gorayski, P.; Pinkham, M.B.; Muir, J.B.; Pullar, A.P. Severe acute radiation dermatitis in a patient with argyria. Case Rep. Oncol. Med. 2014, 2014, 154349. [Google Scholar] [CrossRef]
  216. DiGiorgio, C.M.; Wu, D.C.; Goldman, M.P. Successful treatment of argyria using the Picosecond Alexandrite Laser. Dermatol. Surg. 2016, 42, 431–433. [Google Scholar] [CrossRef] [PubMed]
  217. Jung, I.; Joo, E.J.; Suh, B.S.; Ham, C.B.; Han, J.M.; Kim, Y.G.; Yeom, J.S.; Choi, J.Y.; Park, J.H. A case of generalized argyria presenting with muscle weakness. Ann. Occup. Environ. Med. 2017, 29, 45. [Google Scholar] [CrossRef] [Green Version]
  218. Claessens, D.; Zeitz, P.F.; Beckers, H. Bluish-gray discoloration of skin and conjunctiva. Ophthalmologe 2020, 117, 66–68. [Google Scholar] [CrossRef] [PubMed]
  219. Weiss, E.; Streight, K.L.; Rizk, C.B.; Markus, R. Side-by-side comparison of a Picosecond 755-nm Alexandrite Laser and a Quality-switched 1064-nm Neodymium-doped Yttrium Aluminum Garnet Laser in the treatment of argyria. Cureus 2019, 11, e5206. [Google Scholar] [CrossRef] [Green Version]
  220. Shao, E.X.; Collins, A.; McCallum, N.; Lim, D. Electron nicroscopy of argyria treated with Picosecond Alexandrite Laser. Dermatol. Surg. 2020, 46, 1246–1249. [Google Scholar] [CrossRef]
  221. Simon, M.; Buchanan, J.A. Argyria, an unexpected case of skin discoloration from colloidal silver salt ingestion. J. Emerg. Med. 2020, 59, e39–e41. [Google Scholar] [CrossRef]
  222. Seitz, I.P.; Kowarik, M.C.; Sartor-Pfeiffer, J.; Ziemann, U.; Wilhelm, H.; Bartz-Schmidt, K.U. Occurrence of primary progressive multiple sclerosis in a patient with argyria: Causality or coincidence? Mult. Scler. Relat. Disord. 2020, 46, 102465. [Google Scholar] [CrossRef]
  223. Han, T.Y.; Chang, H.S.; Lee, H.K.; Son, S.J. Successful treatment of argyria using a low-fluence Q-switched 1064-nm Nd:YAG laser. Int. J. Dermatol. 2011, 50, 751–753. [Google Scholar] [CrossRef] [PubMed]
  224. Anderson, E.L.; Janofsky, J.; Jayaram, G. Argyria as a result of somatic delusions. Am. J. Psychiatry 2008, 165, 649–650. [Google Scholar] [CrossRef] [PubMed]
  225. Okan, D.; Woo, K.; Sibbald, R.G. So what if you are blue? Oral colloidal silver and argyria are out: Safe dressings are in. Adv. Ski. Wound Care 2007, 20, 326–330. [Google Scholar] [CrossRef] [PubMed]
  226. Hori, K.; Martin, T.G.; Rainey, P.; Robertson, W.O. Believe it or not—Silver still poisons! Vet. Hum. Toxicol. 2002, 44, 291–292. [Google Scholar] [PubMed]
  227. Tran, H.A.; Song, S. Silver toxicity masquerading as hypocaeruloplasminaemia. Pathology 2007, 39, 456–458. [Google Scholar] [CrossRef]
  228. Baker, C.D.; Federico, M.J.; Accurso, F.J. Case report: Skin discoloration following administration of colloidal silver in cystic fibrosis. Curr. Opin. Pediatr. 2007, 19, 733–735. [Google Scholar] [CrossRef]
  229. Hristov, A.C.; High, W.A.; Golitz, L.E. Localized cutaneous argyria. J. Am. Acad. Dermatol. 2011, 65, 660–661. [Google Scholar] [CrossRef]
  230. Glehr, M.; Leithner, A.; Friesenbichler, J.; Goessler, W.; Avian, A.; Andreou, D.; Maurer-Ertl, W.; Windhager, R.; Tunn, P.U. Argyria following the use of silver-coated megaprostheses: No association between the development of local argyria and elevated silver levels. Bone Jt. J. 2013, 95-B, 988–992. [Google Scholar] [CrossRef]
  231. Naqvi, A.H.; Shields, J.W.; Abraham, J.L. Nasal argyria (deposition of silver-selenium) in the photographic film industry: Histopathology and microanalysis. Am. J. Otolaryngol. 2007, 28, 430–432. [Google Scholar] [CrossRef]
  232. Flögel, W.; Widmeier, S.; Hotz, P.; Schärer, L.; Barthelmes, D.; Landau, K.; Thiel, M.A. Corneal and conjunctival findings in systemic silver intoxication. Klin. Mon. Augenheilkd. 2006, 223, 390–392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  233. Tajirian, A.L.; Campbell, R.M.; Robinson-Bostom, L. Localized argyria after exposure to aerosolized solder. Cutis 2006, 78, 305–308. [Google Scholar]
  234. Cho, E.A.; Lee, W.S.; Kim, K.M.; Kim, S.Y. Occupational generalized argyria after exposure to aerosolized silver. J. Dermatol. 2008, 35, 759–760. [Google Scholar] [CrossRef]
  235. Gallardo, M.J.; Randleman, J.B.; Price, K.M.; Johnson, D.A.; Acosta, S.; Grossniklaus, H.E.; Stulting, R.D. Ocular argyrosis after long-term self-application of eyelash tint. Am. J. Ophthalmol. 2006, 141, 198–200. [Google Scholar] [CrossRef]
  236. Sakai, T.; Yamada, N.; Yamamoto, O.; Saito-Shono, T.; Yamate, T.; Ishikawa, K.; Goto, M.; Hatano, Y.; Hongo, N.; Kodera, T.; et al. Argyria due to embedded acupuncture needles and their transcaval migration into the right ventricle without serious complications. Eur. J. Dermatol. 2017, 27, 655–656. [Google Scholar] [CrossRef] [PubMed]
  237. Suzuki, H.; Baba, S.; Uchigasaki, S.; Murase, M. Localized argyria with chrysiasis caused by implanted acupuncture needles. Distribution and chemical forms of silver and gold in cutaneous tissue by electron microscopy and X-ray microanalysis. J. Am. Acad. Dermatol. 1993, 29, 833–837. [Google Scholar] [CrossRef]
  238. Legat, F.J.; Goessler, W.; Schlagenhaufen, C.; Soyer, H.P. Argyria after short-contact acupuncture. Lancet 1998, 352, 241. [Google Scholar] [CrossRef]
  239. Takeishi, E.; Hirose, R.; Hamasaki, Y.; Katayama, I. Localized argyria 20-years after embedding of acupuncture needles. Eur. J. Dermatol. 2002, 12, 609–611. [Google Scholar]
  240. Rackoff, E.M.; Benbenisty, K.M.; Maize, J.C.; Maize, J.C., Jr. Localized cutaneous argyria from an acupuncture needle clinically concerning for metastatic melanoma. Cutis 2007, 80, 423–426. [Google Scholar]
  241. Alés-Fernández, M.; Ríos-Martín, J.J.; Camacho-Martínez, F.M. Localized argyria secondary to acupuncture mimicking blue nevus. J. Drugs Dermatol. 2010, 9, 1019–1020. [Google Scholar]
  242. van den Nieuwenhuijsen, I.J.; Calame, J.J.; Bruynzeel, D.P. Localized argyria caused by silver earrings. Dermatologica 1988, 177, 189–191. [Google Scholar] [CrossRef] [PubMed]
  243. Morton, C.A.; Fallowfield, M.; Kemmett, D. Localized argyria caused by silver earrings. Br. J. Dermatol. 1996, 135, 484–485. [Google Scholar] [CrossRef]
  244. Newman, M.; Kolecki, P. Argyria in the ED. Am. J. Emerg. Med. 2001, 19, 525–526. [Google Scholar] [CrossRef] [PubMed]
  245. Timmins, A.C.; Morgan, G.A. Argyria or cyanosis. Anaesthesia 1988, 43, 755–756. [Google Scholar] [CrossRef]
  246. Fred, H.L. Case in point. Generalized argyria. Hosp. Pract. 1994, 29, 14. [Google Scholar] [CrossRef] [PubMed]
  247. Faergemann, J. Medical history. Lancet 2002, 360, 689. [Google Scholar] [CrossRef]
  248. Baernstein, A.; Smith, K.M.; Elmore, J.G. Singing the blues: Is it really cyanosis? Respir. Care 2008, 53, 1081–1084. [Google Scholar]
  249. Fernandez-Flores, A.; Nguyen, T.; Cassarino, D.S. Mucocutaneous Hyperpigmentation in a Patient With a History of Both Minocycline and Silver Ingestion. Am. J. Dermatopathol. 2017, 39, 916–919. [Google Scholar] [CrossRef]
  250. Hays, G.B.; Lyle, C.B., Jr.; Wheeler, C.E., Jr. Slate-Gray Color in Patients Receiving Chlorpromazine. Arch. Dermatol. 1964, 90, 471–476. [Google Scholar] [CrossRef]
  251. Trimble, J.W.; Mendelson, D.S.; Fetter, B.F.; Ingram, P.; Gallagher, J.J.; Shelburne, J.D. Cutaneous pigmentation secondary to amiodarone therapy. Arch. Dermatol. 1983, 119, 914–918. [Google Scholar] [CrossRef] [PubMed]
  252. Rhee, D.Y.; Chang, S.E.; Lee, M.W.; Choi, J.H.; Moon, K.C.; Koh, J.K. Treatment of argyria after colloidal silver ingestion using Q-switched 1064-nm Nd:YAG laser. Dermatol. Surg. 2008, 34, 1427–1430. [Google Scholar] [CrossRef]
  253. Parker, W.A. Argyria and cyanotic heart disease. Am. J. Hosp. Pharm. 1977, 34, 287–289. [Google Scholar] [CrossRef]
  254. Kejda, J.; Horák, O.; Janecková, R. Argyria imitating cardiopulmonary cyanosis (author’s transl). Ceskoslovenska Dermatol. 1980, 55, 330–333. [Google Scholar]
  255. Donnard, G.; Sallaberry, M.; Morand, J.J. Argyria and anesthesia. Ann. Fr. Anesth. Reanim. 1996, 15, 226. [Google Scholar] [CrossRef]
  256. Travis, C. Differential diagnosis cyanosis versus argyria: When your patient remains blue—A 48-year-old trauma patient with persistent cyanosis. J. Emerg. Nurs. 2010, 36, 466–467. [Google Scholar] [CrossRef]
  257. Jänner, M.; Marschelke, I.; Voigt, H. Localized intramural silver impregnation of the tongue. Differential diagnosis from malignant melanoma. Hautarzt 1980, 31, 510–512. [Google Scholar] [PubMed]
  258. Landas, S.K.; Mitros, F.A.; Furst, D.E.; LaBrecque, D.R. Lipogranulomas and gold in the liver in rheumatoid arthritis. Am. J. Surg. Pathol. 1992, 16, 171–174. [Google Scholar] [CrossRef] [PubMed]
  259. Hugar, S.B.; Shulman, J.; Yanta, J.; Nine, J. Ochronosis presenting as methemoglobinemia. J. Forensic Sci. 2019, 64, 913–916. [Google Scholar] [CrossRef]
  260. Atmatzidis, D.H.; Hoegler, K.; Weiss, A.; Lambert, W.C.; Schwartz, R.A. Unsafe deposits: Overlapping cutaneous manifestations of porphyria cutanea tarda, ochronosis, hemochromatosis, and argyria. Skinmed 2019, 17, 161–170. [Google Scholar]
  261. Rosenman, K.D.; Moss, A.; Kon, S. Argyria: Clinical implications of exposure to silver nitrate and silver oxide. J. Occup. Med. 1979, 21, 430–435. [Google Scholar]
  262. Bartlett, R.E. Generalized argyrosis with lens involvement; report of an unusual case. Am. J. Ophthalmol. 1954, 38, 402–403. [Google Scholar] [CrossRef]
  263. Pifer, J.W.; Friedlander, B.R.; Kintz, R.T.; Stockdale, D.K. Absence of toxic effects in silver reclamation workers. Scand. J. Work. Environ. Health 1989, 15, 210–221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  264. Spencer, W.H.; Garron, L.K.; Contreras, F.; Hayes, T.L.; Lai, C. Endogenous and exogenous ocular and systemic silver deposition. Trans. Ophthalmol. Soc. U. K. 1980, 100, 171–178. [Google Scholar] [PubMed]
  265. Zech, P.; Colon, S.; Labeeuw, R.; Blanc-Brunat, N.; Richard, P.; Perol, M. Nephrotic syndrome with silver deposits in the glomerular basement membranes during argyria. Nouv. Press. Med. 1973, 2, 161–164. [Google Scholar]
  266. Watanabe, Y.; Eguchi, A.; Kamio, M.; Yamaguchi, K.; Ohara, M.; Mochizuki, T. Case of membranous nephropathy associated with argyria. Nihon Jinzo Gakkai Shi 2005, 47, 547–551. [Google Scholar]
  267. McCague, A.; Joe, V.C. A Case of Argyria and Acute Leukopenia Associated with the Use of an Antimicrobial Soft Silicone Foam Dressing. J. Burn Care Res. 2016, 37, e493–e496. [Google Scholar] [CrossRef]
  268. Rezk, T.; Penton, J.; Stevenson, A.; Owen-Casey, M.; Little, M.; Cunningham, J.; Salama, A.D. Pauci Immune crescentic glomerulonephritis in a patient with T-cell lymphoma and argyria. BMC Nephrol. 2016, 17, 49. [Google Scholar] [CrossRef] [Green Version]
  269. Parkes, A. Silver-coated dressing Acticoat. J. Trauma 2006, 61, 239–240. [Google Scholar] [CrossRef]
  270. Barrie, H.J.; Harding, H.E. Argyro-siderosis of the lungs in silver finishers. Occup. Environ. Med. 1947, 4, 225–229. [Google Scholar] [CrossRef] [Green Version]
  271. Harding, H.E. Fibrosis in the lungs of a silver finisher. Br. J. Ind. Med. 1948, 5, 70–72. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  272. Stepien, K.M.; Morris, R.; Brown, S.; Taylor, A.; Morgan, L. Unintentional silver intoxication following self-medication: An unusual case of corticobasal degeneration. Ann. Clin. Biochem. 2009, 46, 520–522. [Google Scholar] [CrossRef]
  273. Stepien, K.M.; Taylor, A. Colloidal silver ingestion with copper and caeruloplasmin deficiency. Ann. Clin. Biochem. 2012, 49, 300–301. [Google Scholar] [CrossRef] [PubMed]
  274. Graham, S.A.; O’Meara, J.M. The feasibility of measuring silver concentrations in vivo with X-ray fluorescence. Phys. Med. Biol. 2004, 49, N259–N266. [Google Scholar] [CrossRef]
  275. Czitober, H.; Frischauf, H.; Leodolter, I. Quantitative studies in generalized argyron’s using neutron activation analysis. Virchows Arch. A Pathol. Pathol. Anat. 1970, 350, 44–51. [Google Scholar] [CrossRef]
  276. Johansson, E.A.; Kanerva, L.; Niemi, K.M.; Lakomaa, E.L. Generalized argyria with low ceruloplasmin and copper levels in the serum. A case report with clinical and microscopical findings and a trial of penicillamine treatment. Clin. Exp. Dermatol. 1982, 7, 169–176. [Google Scholar] [CrossRef] [PubMed]
  277. Rosenthal, T.; Ollswang, A. Failure of 2,3-dimercaptopropanol in treatment of argyria. Arch. Derm. Syphilol. 1948, 57, 743–745. [Google Scholar] [CrossRef] [PubMed]
  278. Kleckner, M.S., Jr. The use of BAL in generalized argyria. Calif. Med. 1949, 70, 133. [Google Scholar] [PubMed]
  279. Aaseth, J.; Halse, J.; Falch, J. Chelation of silver in argyria. Acta Pharmacol. Toxicol. (Copenh.) 1986, 59 (Suppl. S7), 471–474. [Google Scholar] [CrossRef] [PubMed]
  280. Almurayshid, A.; Park, S.; Oh, S.H. Effective laser treatment options for argyria: Review of literatures. J. Cosmet. Dermatol. 2020, 19, 1877–1882. [Google Scholar] [CrossRef] [PubMed]
  281. Park, S.W.; Kim, J.H.; Shin, H.T.; Lee, K.T.; Lee, J.H.; Lee, D.Y.; Lee, J.H.; Yang, J.M. An Effective Modality for Argyria Treatment: Q-Switched 1064-nm Nd:YAG Laser. Ann. Dermatol. 2013, 25, 511–512. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  282. Hovenic, W.; Golda, N. Treatment of argyria using the quality-switched 1064-nm neodymium-doped yttrium aluminum garnet laser: Efficacy and persistence of results at 1-year follow-up. Dermatol. Surg. 2012, 38, 2031–2034. [Google Scholar] [CrossRef] [PubMed]
  283. Krase, J.M.; Gottesman, S.P.; Goldberg, G.N. Recurrence of Argyria Post Q-Switched Laser Treatment. Dermatol. Surg. 2017, 43, 1308–1311. [Google Scholar] [CrossRef] [PubMed]
  284. Mock, J.J.; Barbic, M.; Smith, D.R.; Schultz, D.A.; Schultz, S. Shape effects in plasmon resonance of individual colloidal silver nanoparticles. J. Chem. Phys. 2002, 116, 6755–6759. [Google Scholar] [CrossRef]
  285. Jańczuk, Z.; Banach, J. Local argyrosis of oral mucosa or amalgam tattoo. A problem in diagnosis and treatment. Adv. Med. Sci. 2006, 51 (Suppl. S1), 62–65. [Google Scholar] [PubMed]
  286. Munger, M.A.; Radwanski, P.; Hadlock, G.C.; Stoddard, G.; Shaaban, A.; Falconer, J.; Grainger, D.W.; Deering-Rice, C.E. In vivo human time-exposure study of orally dosed commercial silver nanoparticles. Nanomedicine 2014, 10, 1–9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  287. Gonzalez, C.; Rosas-Hernandez, H.; Ramirez-Lee, M.A.; Salazar-García, S.; Ali, S.F. Role of silver nanoparticles (AgNPs) on the cardiovascular system. Arch. Toxicol. 2016, 90, 493–511. [Google Scholar] [CrossRef] [PubMed]
  288. Abukabda, A.B.; Stapleton, P.A.; Nurkiewicz, T.R. Metal Nanomaterial Toxicity Variations Within the Vascular System. Curr. Environ. Health Rep. 2016, 3, 379–391. [Google Scholar] [CrossRef] [Green Version]
  289. Teran, C.G.; Sura, S.; Cabandugama, P.; Berson, C. Silver nitrate ingestion: Report of a case with an uneventful course and review of the literature. Clin. Pract. 2011, 1, e43. [Google Scholar] [CrossRef] [PubMed]
  290. Shoults-Wilson, W.A.; Reinsch, B.C.; Tsyusko, O.V.; Bertsch, P.M.; Lowry, G.V.; Unrine, J.M. Effect of silver nanoparticle surface coating on bioaccumulation and reproductive toxicity in earthworms (Eisenia fetida). Nanotoxicology 2011, 5, 432–444. [Google Scholar] [CrossRef]
Figure 1. Characteristic bluish-grayish signs of generalized argyria, namely in sun-exposed areas of the head, neck, and hands. Reprinted from (A,G)—[20], (B)—[58], (C)—(Today media news), (D)—[34], (E)—[59], (F)—[47] and (H)—[60].
Figure 1. Characteristic bluish-grayish signs of generalized argyria, namely in sun-exposed areas of the head, neck, and hands. Reprinted from (A,G)—[20], (B)—[58], (C)—(Today media news), (D)—[34], (E)—[59], (F)—[47] and (H)—[60].
Jcm 10 02086 g001
Figure 2. Characteristic bluish-gray discoloration of the nails (azure lunula), namely of the lunula due to silver exposure. In D comparison with regular nails is provided. Reprinted from (A)—[67], (B)—[68], (C)—[66], and (D)—[69].
Figure 2. Characteristic bluish-gray discoloration of the nails (azure lunula), namely of the lunula due to silver exposure. In D comparison with regular nails is provided. Reprinted from (A)—[67], (B)—[68], (C)—[66], and (D)—[69].
Jcm 10 02086 g002
Figure 3. Characteristic dark-bluish-grayish macules of localized argyria following a silver jewelry nose piercing (A), acupuncture treatment (B), silver jewelry in the index finger (C), and macule-mimicking a nevus (D). Discoloration of the leg over a silver-coated megaprosthesis used for distal femoral osteosarcoma (E). Reprinted from (A)—[88], (B)—[89], (C)—[87], (D)—[73] and (E)—[90].
Figure 3. Characteristic dark-bluish-grayish macules of localized argyria following a silver jewelry nose piercing (A), acupuncture treatment (B), silver jewelry in the index finger (C), and macule-mimicking a nevus (D). Discoloration of the leg over a silver-coated megaprosthesis used for distal femoral osteosarcoma (E). Reprinted from (A)—[88], (B)—[89], (C)—[87], (D)—[73] and (E)—[90].
Jcm 10 02086 g003
Figure 4. Amalgam tattoo characterized by the dark-blue macule on the buccal mucosa near a restored tooth. Reprinted from (A,B)—[95], (C)—[110].
Figure 4. Amalgam tattoo characterized by the dark-blue macule on the buccal mucosa near a restored tooth. Reprinted from (A,B)—[95], (C)—[110].
Jcm 10 02086 g004
Figure 5. Ocular argyrosis characterized by intense dark pigmentation of the palpebral conjunctiva, with a more discrete bluish hue of the bulbar conjunctive (A) and of the palpebral conjunctiva (B,C), mimicking a conjunctival melanoma. Reprinted from (A)—[123], (B,C)—[119].
Figure 5. Ocular argyrosis characterized by intense dark pigmentation of the palpebral conjunctiva, with a more discrete bluish hue of the bulbar conjunctive (A) and of the palpebral conjunctiva (B,C), mimicking a conjunctival melanoma. Reprinted from (A)—[123], (B,C)—[119].
Jcm 10 02086 g005
Figure 6. Laser treatment of argyria of the face and neck before and after a single pass of a Q-S 1064 nm Nd:YAG laser (A,B), notorious discoloration lightening of the right half of the forehead (C), and visible contrast between untreated (neck) and treated (face) areas (D). Reprinted from (A,B)—[63], (C)—[252] and (D)—[282].
Figure 6. Laser treatment of argyria of the face and neck before and after a single pass of a Q-S 1064 nm Nd:YAG laser (A,B), notorious discoloration lightening of the right half of the forehead (C), and visible contrast between untreated (neck) and treated (face) areas (D). Reprinted from (A,B)—[63], (C)—[252] and (D)—[282].
Jcm 10 02086 g006
Figure 7. Major characteristics of different forms of argyria.
Figure 7. Major characteristics of different forms of argyria.
Jcm 10 02086 g007
Table 1. Overview of major causes of argyria.
Table 1. Overview of major causes of argyria.
TreatmentCauseReferences
Gastrointestinal conditions (ingestion of silver-containing colloids/pills)Iatrogenic, systemic[135,166,167,168,169,170,171,172,173,174]
Leukoplakia patch (topical application of silver nitrate)Iatrogenic, topical[175]
Epilepsy and other neuropsychiatric conditions (ingestion of silver-containing pills)Iatrogenic, systemic[40,131,176,177]
Alopecia (ingestion of silver-containing colloids)Iatrogenic, systemic[52]
Prophylaxis of gonococcal ophthalmia neonatorum (application of silver nitrate collyrium)Iatrogenic, topical[46,105,178]
Syphilis (topical application of silver arsphenamine)Iatrogenic, topical[126,131]
Wounds/ulcers/burns (topical application of silver sulfadiazine cream for asepsis, silver nitrate for chemical cautery/hemostasis, and/or use of silver-impregnated suture threads/surgical clips)Iatrogenic, topical and/or systemic (if bloodstream is reached)[70,84,85,105,128,141,179,180,181,182,183,184,185,186,187]
Strabismus surgery (application of silver nitrate collyrium and/or use of silver-impregnated suture threads/surgical clips)Iatrogenic, topical[160,161,188]
Trachoma (topical application of silver nitrate for chemical cautery)Iatrogenic, topical[121]
Conjunctivitis/eye soreness/epiphora (application of silver-containing collyrium)Iatrogenic, topical[114,153,154,189,190]
Pharyngitis/throat soreness (topical throat application of pulverized silver and/or ingestion of silver-containing tablets)Iatrogenic, topical (pharyngeal) and/or systemic[67,144,191,192,193,194]
Hematuria (instillation of the urinary tract with silver nitrate preparations)Iatrogenic, topical[105,106,107]
Smoking cessation (chewing/ingestion of silver-coated sugar particles and/or silver acetate lozenges/pills)Iatrogenic, systemic[57,126,195,196,197,198]
Varicose veins (injection of silver nitrate as sclerosant)Iatrogenic, topical, and/or systemic[130]
Intractable diplopia (use of silver nitrate-coated soft lenses)Iatrogenic, topical[199]
Antiseptic and astringent properties (application of silver-containing vasoconstricting nose drops)Iatrogenic, topical, and/or systemic (silver is drained posteriorly and ingested)[5,40,47,55,59,64,126,134,186,200,201,202,203,204,205]
Dental restoration (silver-containing filling material for endodontic procedures)Iatrogenic, topical[92,93,94,96,97,98,100,185,206,207,208,209]
Halitosis (silver-containing breath-freshening pills)Non-medical, systemic[8,210]
Belief in general health benefits/immune system boosting/alternative medicine (ingestion of silver-containing colloids, application of silver-containing nasal drops)Non-conventional medicine, systemic[1,6,9,20,22,34,38,44,45,49,50,51,58,62,66,68,69,125,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228]
Skin-breaching trauma with silver-containing materialAccidental, topical[145,229]
Antibiotic properties (use of silver-coated prosthetic implants)Iatrogenic, topical, and/or systemic (if bloodstream is reached)[90,230]
Photochemical industryOccupational, topical (skin, eye, and intranasal deposition), and/or systemic (inhalation)[112,152,231]
Occupational silver manipulation, silver soldering/silversmithing in jewelry/art craftingOccupational, topical (skin and eye) and/or systemic (inhalation)[54,77,80,119,122,150,163,232,233,234]
Eyelash tintingNon-medical, topical[115,235]
AcupunctureNon-conventional medicine, topical[8,89,98,139,140,236,237,238,239,240,241]
Silver earrings/piercingsNon-medical, topical[2,71,72,74,88,137,138,165,242,243]
Silver-coated nuts and/or spices (areca and betel nut)Non-medical, systemic (oral intake)[7,91]
Table 2. Differential diagnosis for other argyria-mimicking pigmentations of skin and other tissues. GA, generalized argyria; LA, localized argyria.
Table 2. Differential diagnosis for other argyria-mimicking pigmentations of skin and other tissues. GA, generalized argyria; LA, localized argyria.
Pathological Condition of XenobioticDescriptionReferences
HemochromatosisGeneralized skin hyperpigmentation (GA)[40,56,64,69,126,134,167,178,245,246,247]
Lead poisoningBlue line along the gingival margins at the base of the teeth (LA/amalgam tattoo)[5,7,40,91]
Methemoglobinemia/sulfhemoglobinemiaGeneralized skin brownish-blue to gray pigmentation (as in cyanosis) (GA)[4,40,56,126,134,141,178,245,246,248]
Toxic melanodermatitisHyperpigmented skin lesions (LA, GA)[132]
MinocyclineBlue staining of teeth or blue-gray skin lesions (GA)[7,64,132,249]
Chlorpromazine/PhenothiazinesSlate gray-bluish skin discoloration in sun-exposed areas (GA)[64,132,178,250]
AmiodaroneSlate gray-bluish skin discoloration in sun-exposed areas (GA)[7,64,125,251]
Antimalarial agentsBlue-gray discolorations of the mouth and skin (LA, GA)[55,79,132,246]
ClofazimineGrayish skin plaques or generalized gray skin pigmentation (LA, GA)[7,132]
Cyanosis/cyanotic heart diseaseGeneralized skin brownish-blue to gray pigmentation (GA)[1,8,20,36,40,43,45,53,56,66,69,131,169,178,200,245,246,248,252,253,254,255,256]
NevusFlat or raised pigmented skin lesion (LA)[2,71,73,76,82,133,137,164,229,241]
End-stage renal disease/uremiaHeterogenous skin lesions (LA, GA)[36]
Melanoma of the skin/conjunctiva/oral mucosaPigmented lesion, usually asymmetric, with heterogenous color and time-evolving (LA/amalgam tattoo)[23,82,92,95,96,100,101,119,133,159,178,188,240,246,257]
ChrysiasisSlate-gray to blue skin pigmentation, especially in sun-exposed areas, nail pigmentation (LA, GA, azure lunula)[36,64,79,113,178,237,246,258]
Iron saltsBrown to red skin lesions (LA)[79]
OchronosisBluish-black skin lesions (LA, GA)[64,76,113,259,260]
Wilson’s diseaseGeneralized skin hyperpigmentation, Kayser-Fleischer rings (GA, OA)[55,113]
Tobacco (chewing)Brownish-black staining of the oral mucosa (LA/amalgam tattoo)[91]
Chlorophyll (mouthwash)Blackening of the tongue (LA/amalgam tattoo)
Sodium perborate (mouthwash)Blackening of the tongue (LA/amalgam tattoo)
AriboflavinosisDiffuse bluish-purple discoloration of the buccal mucosa (GA)
Peutz-Jeghers syndromeDark blue-brown hyperpigmented gingival macules (LA/amalgam tattoo)
Addison’s diseaseGeneralized bronze-like skin pigmentation, diffuse pigmentation of gingiva, tongue, and buccal mucosa (GA)[53,58,69,91,134,178,214,245]
BismuthosisBlue-black, sharply limited pigmentation of marginal gingivae, nail pigmentation (LA/amalgam tattoo, GA, azure lunula)[36,79,91,134,178,246]
MercurialismDiffuse blue-gray to black gingival pigmentation, nail pigmentation (LA/amalgam tattoo, azure lunula)[36,79,91,140,178]
ArseniasisGeneralized skin hyperpigmentation with hyperkeratosis (GA)[5,7,79,91]
Accidental tattooDark-blue/black macules/patterns (LA)[133]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Mota, L.; Dinis-Oliveira, R.J. Clinical and Forensic Aspects of the Different Subtypes of Argyria. J. Clin. Med. 2021, 10, 2086. https://doi.org/10.3390/jcm10102086

AMA Style

Mota L, Dinis-Oliveira RJ. Clinical and Forensic Aspects of the Different Subtypes of Argyria. Journal of Clinical Medicine. 2021; 10(10):2086. https://doi.org/10.3390/jcm10102086

Chicago/Turabian Style

Mota, Luís, and Ricardo Jorge Dinis-Oliveira. 2021. "Clinical and Forensic Aspects of the Different Subtypes of Argyria" Journal of Clinical Medicine 10, no. 10: 2086. https://doi.org/10.3390/jcm10102086

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop